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1. INTRODUCTION
Peptic ulcer is naturally a chronic disease with frequent exacerbations which 
can last 20-30 years (Penston, 1990). The pathology of gastric ulcer was first 
described by Creuveilhier in 1835 (Creuveilhier, 1835). Having changed from a 
rare disease in the 19th century to one of the most common conditions in the hu­
man by the middle of the 20th century, peptic ulcer has shown the tendency to 
decline in incidence in developed countries since the 1950s (Coggon et al., 
1981). At the same time, significant geographical and regional differences have 
been established in the prevalence of peptic ulcer (May, 1985; Weir et al., 1968; 
Kurata et al., 1984).
Perforated peptic ulcer (PPU), a serious and potentially fatal complication of 
peptic ulcer disease, was first described already in 1843 (Crisp, 1843). In about 
10% of population, peptic ulcer disease develops during lifetime (Langman,
1979), while the incidence of (PPU) between 2.3 and 10.0 has been reported 
from developed countries in recent decades (Aeberhard et al., 1990; Hermans- 
son et al., 1997; Mäkelä et al., 1992). In recent decades, PPU incidence has 
decreased in young patients and males but has increased in elderly patients and 
females (Svanes, 2000). Use of NSAIDs among PPU patients, as well as the 
rate of concomitant diseases and complications have increased (Aeberhard et 
al., 1990; Svanes et al., 1993; Bliss et al., 1991; Bulut et al., 1996; Suter, 1995).
In Estonia, according to the reports of the Ministry of Social Affairs of 
Estonia, the number of emergency operations for PPU per year has increased 
about 2.5-fold since 1991. The reasons for such an increase have not yet been 
evaluated. They could be related to changes in the factors involved in the 
pathogenesis and course of ulcer disease, as well as to the extensive use of 
ulcerogenic medicines in community, changes in the policies of the medical 
treatment of ulcer, changes in the circulating strains of H. pylori, etc. Moreover, 
it is important to assess whether the changes involve groups of the working 
population as well as to identify the role that socio-economic factors could play 
in Estonia where fast changes have taken place in the political situation.
Treatment policies for PPU in developed countries have changed as well. 
Easy nondefinitive operations, not altering the pathogenetic mechanisms of 
ulcer disease, have gained prevalence (Roher et al., 1996; Druart et al., 1997). 
Such changes in tactics are based mainly on availability of new powerful 
medicines and introduction of H. pylori treatment in management. At the same 
time, unlike another ulcer disease complication, ulcer haemorrhage (Sonnen- 
berg et al., 1999; Laine, 1995), in PPU the long-term results of this treatment 
tactics have not been adequately published. Nor has the role of H. pylori itself 
been unambiguously identified in ulcer perforation. (Reinbach et al., 1993; 
Sebastian et al., 1995; Matsukura et al., 1997). In addition, a large number of 
studies are focused on the evaluation of different H. pylori strains and the 
relationships of the virulence markers of bacteria with development of different
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gastric diseases (Rudi et al., 1998; Strobel et al., 1998; van Doom et a l, 1998). 
However, these correlations have not yet been unambiguously clarified (Maeda 
et al., 1998; Atherton et al., 1997).
Problems of peptic ulcer and gastric surgery have already been studied for 
several decades in Estonia and at the Tartu University Clinic of Surgery (Sarv, 
1968; Sibul et al., 1968; Truve et al., 1973; Lutsuver, 1978; Peetsalu et al., 
1991; Väli et al., 1994; Vardja et al., 1996; Soplepmann et al., 1997; Peetsalu et 
al., 1998). The present investigation continued this work focusing on ulcer 
complication, PPU, whose incidence seemed to have been increased signifi­
cantly in our patients since the last decade. The study dealt mainly with the 
following aspects: epidemiology of PPU in the last two decades, possible risk 
factors for PPU, evaluation of the effect of different surgical treatment strate­
gies on outcome and relationship of PPU with H. pylori, including evaluation of 
postoperative eradication regimens in our patients.
The purpose of the investigations was also to support the elaboration of 
evidence based guidelines for PPU treatment in Estonia by providing cor­
responding regional and national data.
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2. REVIEW OF THE LITERATURE
2.1. Epidemiology of PPU
A large number of international data indicate that the epidemiology of PPU has 
undergone considerable changes in developed countries in recent decades. Sub­
jects bom after the turn of the 20th century have carried a high risk for PPU 
throughout their lives; the increasing ulcer risk among the elderly today is 
related to the aging of these high risk cohorts; in younger generations the 
incidence is decreasing (Svanes, 2000). Mean age of patients at the time of 
perforation has risen by 10-20 years (Svanes et al., 1993; Hermansson et al.,
1997). Being previously a disease affecting predominantly men (malerfemale 
ratio about 10:1), PPU is now increasingly affecting elderly women in 
developed countries (male:female ratio about 1.5:1) (Svanes et al., 1993). Use 
of non-steroidal anti-inflammatory drugs among PPU patients, as well as the 
rate of concomitant diseases and complications have increased considerably 
(Aeberhard et al., 1990; Hermansson et al., 1997; Bliss et al., 1991; Bulut et al., 
1996; Suter, 1995). The increasing proportion of women among PPU patients is 
suggested to be influenced by a rising prescription rate for NSAIDs among 
elderly women and the higher life expectancy of women (Mäkelä et al., 1992; 
W altetal., 1986).
The location of ulcer has also changed. In Crisp’s series (Crisp, 1843) gastric 
ulcer perforations accounted for about 70% of all perforations among which 
half were close to the cardia. In the middle of the 20th century most perforations 
were located in the duodenum (Jamieson, 1955). At the end of the 20th century 
there was described a certain increasing tendency for praepyloric and gastric 
ulcer perforations (Svanes et al., 1993; Aeberhard et al., 1990; Tonnesen et al., 
2001). Patients with perforated gastric ulcers are often elderly (Svanes et al., 
1993; Lanng et al., 1988), predominantly females (Lanng et al., 1988).
The rate of mortality has not declined during recent decades despite of the 
progress of medical care. Mortality is reported to vary between 5-31% (Aeber­
hard et al., 1990; Svanes et al., 1993; Bulut et al., 1996; Suter, 1995; Khorso- 
vani et al., 1994; Hermansson et al., 1997) in different studies. Today most 
deaths occur when patients have concomitant serious illness; the slight increase 
in death and complication rates during recent decades can be ascribed largely to 
older and generally more ill patients (Svanes et al., 1993). Mortality rates differ 
significantly in young patients and in those over 70 years (Hermansson et al., 
1997; Irvin, 1989), being nearly 0% in patients under age 50 years and over 30 
% in patients over 70 years.
Majority of peptic ulcer perforations now occur in previously undiagnosed 
ulcers, being often the first manifestation of ulcer disease (Gunshefski et al., 
1990). Also, increase in treatment delay seems to be part of a general trend, 
which has a certain impact on nonimproving mortality (Svanes et al., 1993;
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Bodner et a l, 1990; Horowitz et a l, 1989). Using multifactor analysis Svanes et 
all found that unchanging mortality rates are at least partly masked by the fact 
that increasingly older patients are undergoing surgery and the advances in 
anesthesia and in peri- and postoperative care could be seen if different age 
groups were analysed (Svanes et a l, 1989).
At the same time, no information of the above described trends among the 
Estonian population is available, and it is unclear whether similar changes have 
occurred in Eastern Europe.
2.2. Risk factors related to PPU development
Smoking seems to be one of the main risk factors for PPU, especially in persons 
aged under 70 (Svanes et a l, 1997; Reinbach et a l, 1993; Svanes, 2000). 
Smoking has been shown to increase the risk for ulcer perforation about tenfold 
both among men and women. (Svanes et a l, 1997; Andersen et a l, 2001).
Use of NSAIDs is another well proven important risk factor for ulcer per­
foration, which increases the risk five- to eightfold (Rodriquez et al, 1994; 
Svanes et a l ,  1996; Bliss et al., 1991).
PPU has been associated with social stress (Lam et a l, 1995; Jamieson, 
1955; Cleave, 1962), and suicide rate has been pointed out as an indirect stress 
parameter (Schneider, 1973). Suicide rate has been increasing rapidly in Estonia 
starting from 1991 (Wasserman et a l, 1994), however, it has not yet been 
evaluated whether the PPU and suicide rates were statistically correlated.
Development of perforation in peptic ulcer patients has also been related to 
the following risk factors: alcohol consumption (Sharma et a l, 1997; Andersen 
et al., 2001), use of crack-cocaine (Sharma et al., 1997) and partial type of 
hunger, Ramadan (Donderici et al., 1994). The influence of birth cohort trends 
in PPU prevalence has been suggested as well, i.e. the disease risk follows 
particular birth cohorts (Svanes et a l, 1995). Subjects bom at the beginning of 
the 20th century carried a high risk for PPU, while subjects bom before the turn 
of the century, or more recent birth cohorts showed lower incidence (Svanes, 
2000).
The importance of the main factor in the pathogenesis of ulcer disease, H. 
pylori infection, is not clear in perforated peptic ulcer. In contrast with opinions 
in favour of the cmcial role of H. pylori (Sebastian et al., 1995; Tokunaga et al., 
1998; Ng et al., 1997; Mihmanli et al., 1998) several researchers have opposed 
this idea (Reinbach et a l, 1993; Matsukura et al., 1997; Chowdhary et al, 
1998; Beales, 1998), maintaining that PPU represents even a specific subgroup 
of peptic ulcer disease (Beales, 1998). The divergence of studies may be partly 
attributed to the differences in the methods used in H. pylori detection, or to the 
ethnic diversity of patients (Tokunaga et al., 1998). Also, differences in
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H. pylori strains and host factors can serve as important factors (Matsukura et 
al., 1997).
Prevention of ulcer perforation can be achieved through avoidance of 
smoking; this is an aspect that may play a greater role in ulcer surgery, 
compared even with H. pylori eradication (Svanes, 2000).
There is lack of data about these risk factors in Estonian PPU patients, 
although it was reported, that the prevalence of H. pylori in whole Estonian 
population (up to 87%) is higher than in most European countries (Maaroos,
1995).
2.3. Treatment strategies in PPU and 
risk factors for mortality
The surgical treatment of perforated peptic ulcer dates from the year 1880, 
when Mikulicz sutured a perforated gastric ulcer for the first time (Mikulicz, 
1885). Conservative management of PPU (intravenous fluid resuscitation, anti­
biotics, nasogastric suction and acid reducing pharmacotherapy) as an alterna­
tive to surgery in selected patients was first advocated by Tylor in 1946 (Tylor, 
1946). Although some studies with good results were published (Tylor, 1946; 
Crofts et al., 1989) this strategy was never generally accepted, as conservative 
treatment includes some risk for safety of diagnosis and difficulties with conti­
nuous clinical monitoring as well as significant disadvantages in the case of 
delayed laparotomy (Hölscher et al., 2001). Today most centres prefer surgical 
methods in treatment of PPU.
In recent decades, since the introduction of the H2-receptor antagonists in 
1978, a substantial decrease has occurred in the number of elective operations 
for peptic ulcer, whereas the number of emergency operations due to ulcer 
complications (including PPU) has remained the same (Aeberhard et al., 1990; 
Paimela et al., 1991; Welch et al., 1986; Towfight et al., 2002). With a new 
understanding of peptic ulcer pathogenesis and the advent of new powerful 
medicines, simple operations as ulcer suturation, including laparoscopic mana­
gement, have been increasingly advocated for optimal surgical treatment of 
PPU in recent years (Cocks, 1992; Al-Assi et al., 1994; Lau et a l, 1995; Roher 
et a l, 1996; Druart et a l, 1997; De Boer, 1997; Tran et al., 2002). However, 
there exists a certain controversy in this issue. Numerous data give evidence of 
better long-term results after definitive operation: recurrence rate is lower and 
the patient’s self-estimation of his/her condition is higher (Jordan et a l, 1995; 
Robles et a l, 1995; Peetsalu et a l, 1994; Tsugawa et a l, 2001). At the same 
time, the advantage of H. pylori eradication for PPU patients, which has been 
demonstrated to reduce recurrent ulceration and rebleeding in peptic ulcer 
hemorrhage (Sonnenberg et al., 1999; Laine et a l, 1995) and which is the main 
factor bringing about such fast changes in surgical treatment, is not yet clear.
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Furthermore, the increasing proportion of H. pylori negative patients with ulcer 
complications, especially among elderly patients (Laine et al., 1998; Maher et 
al., 1997), and the fact that eradication rates do not reach 100% despite any 
efforts, indicates that the role of surgery cannot be fully abandoned in these 
patients. Thus Donovan et al proposed considering H. pylori negative patients 
as candidates for definitive ulcer-curative operation (Donovan et al., 1998).
Several studies discussing the safety of and risk factors for definitive surgery 
in an emergency situation have established that definitive surgery in an 
emergency situation is as safe as nondefinitive surgery (Gunshefski et al., 1990; 
Boey et al., 1982; Evans et al., 1997), even in high risk patients (Hamby et al., 
1993; Schein et al., 1990).
Higher age, delayed treatment, presence of concomitant diseases, presence 
of shock on admission, immunocompromised state, low blood hemoglobin 
level, low albumin concentration, leucocyte count less than 9,500/mm3 and 
location of ulcer in the gastric corpus have been pointed out as the risk factors 
for complications and mortality (Suter, 1995; Khorsovani et al., 1994; Svanes et 
al., 1989; Evans et al., 1997; Wakayama et al., 1994; McIntosh et al., 1996; So 
et al., 2000; Chan et al., 2000; Tsugawa et al., 2001). Mortality risk increases 
rapidly if multiple independent risk factors occur in a person and reach up to 
100% when three or more of the above mentioned risk factors coexist (Chan et 
al., 2000; Boey et al., 1987).
There has not been found any correlation between mortality and smoking or 
alcohol use in PPU patients (McIntosh et al., 1996; Bodner et al., 1990; Horo­
witz et al., 1989).
Nor have the factors determining outcome after surgical treatment in 
Estonian PPU patients been analysed before.
2.4. Helicobacter pylori and PPU
In 1982, a spiral-shaped bacterium occurring in the human stomach (Marshall, 
1983; Warren, 1983), known nowadays as Helicobacter pylori, was isolated for 
the first time. The discovery of H. pylori infection has transformed our 
understanding of the patogenesis of peptic ulcer disease (McColl, 1997). H. 
pylori is probably one of the commonest chronic bacterial infections found in 
humans which is distributed in the whole world and is associated with several 
gastric diseases as chronic gastritis, peptic ulcer, gastric cancer and MALT 
(mucosal-associated lymphoid tissues) gastric lymphoma. H. pylori infection is 
more frequent among the population of developing countries (80-90%) 
compared with the population of developed countries (50%) (Glupczynski, 
1996). The infection is mostly acquired in childhood and is often lifelong. It is 
thought that spread of H. pylori infection is related to socio-economic situation 
rather than to racial belonging (Malaty et al., 1992).
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Despite the widespread distribution of H. pylori in the world, the pathway of 
dissemination of the infection is yet unclear. In most cases, the spread is 
considered to be fecal-oral, primarily in developing countries where an impor­
tant role is evidently played by contamination of water (Klein et al., 1991; 
Lindkvist, 1999).
In majority of persons the course of H. pylori infection is asymptomatic. 
This circumstance raises a very important problem, namely, if the difference 
between different host organisms in response to H. pylori infection is the case, 
or if only certain H. pylori strains possess virulent markers needed for damaging 
the gastric mucosa. These relationships have not been clarified until now.
2.4.1. Prevalence of H.pylori infection in PPU patients
The prevalence of H. pylori infection nowadays is about 50% in western 
populations (The EU ROGA ST Study Group, 1993), ranging between about 
20% in 20-years-olds and more than 70% in those over 70 years (Cullen et al., 
1993; Veldhuyzen van Zanten et al., 1994; Kosunen et al., 1989). In Estonia H. 
pylori infection was found in 78-87% of the adult population studied and, 
according to immunological studies, the H. pylori was positive in 87% of 
Estonian adults and in 56% of schoolchildren (Maaroos, 1995; Vorobjova et al., 
1994; Vorobjova et al., 1998). At the same time, its prevalence in PPU patients 
is described to vary between 50 and 96% (Reinbach et al., 1993; Sebastian et 
al., 1995; Matsukura et al., 1997, Tran et al., 2002). The prevalence of H. pylori 
in Estonian PPU patients has not yet been studied.
2.4.2. H. pylori genotypes
To date, several products of H. pylori genes like vac A and its subtypes and 
cagA, acting as disease associated pathogenic factors in infected persons, have 
been identified (Atherton et al., 1995; Atherton et al., 1997; Censini et al.,
1996).
The vacA gene is present in all H. pylori strains, but only approximately 50% 
of them can produce cytotoxin inducing vacuolisation of gastric epithelial cells 
(Cover et al., 1992; Atherton et al., 1995), the cause of this being actually 
different intensities of toxin production (Reyrat et al., 1999).
In addition, vacA alleles occur with different genotype variations (mosaic 
pattern) where three different families of signal sequences (sia, sib  and s2) and 
two different families of middle-region alleles (ml and m2) were initially 
distinguished (Atherton et al., 1995). By now, a number of different middle- 
region types have been additionally found (mla, m lT  and mlTm2, m lb and
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mlb-m2) (Pan et al., 1998; Wang et al., 1998) and one more subtype of the 
signal sequence, sic , has been added (van Doom et al., 1998).
About 60% of H. pylori strains possess the cagA gene, among which nearly 
all produce CagA protein (Tummuru et al., 1993). CagA is thought to be as­
sociated with the cytotoxic activity of a H. pylori strain (Cover et al., 1990; 
Tummuru et al., 1993).
The virulent cytotoxin VacA and CagA producing strains are described to be 
more common among patients with peptic ulcer and gastric cancer (Atherton et 
al., 1997; Cover et al., 1994). However, in Asia the high prevalence of CagA 
positivity has hampered its use as a virulent marker of H. pylori strains (Shi- 
moyama et al., 1997; Pan et al., 1997). A study performed in Japan found no 
significant difference in the prevalence of the virulence factors between the H. 
pylori strains isolated from patients with peptic ulcers and chronic gastritis 
(Tokumaru et al., 1999).
According to published studies (Atherton et al., 1997; Cover et al., 1994; 
van Doom et al., 1998) the vacA si a/ml subtype is considered more cytotoxic 
and more related to development of peptic ulcer disease compared with the 
sla/m2 and s2/m2 vacA genotypes.
However, the relationship between development of different gastric diseases 
and the vimlence markers of H. pylori strains has not been investigated in a 
large number of different populations.
A key feature of H. pylori is the enormous genomic diversity of the strains 
distributed over the globe. It has even been suggested that many individuals 
appear to be infected by a unique strain (Owen, 1998).
In contrast, a particular geographic pattern of different H. pylori genotypes 
seems to be characteristic of different countries (Ito et al., 1997; Rudi et al.,
1998). In Western populations, gastric atrophy, duodenal ulceration, intestinal 
metaplasia and gastric carcinoma are more common among patients infected 
with cagA positive (and vacA si subtype) than among patients infected with 
cagA negative strains (Atherton et al., 1995 and 1997). Yet in China and Japan,
H. pylori strains possessing or lacking the cagA gene were equally frequent 
among diseased and control patients (Ito et al., 1997; Pan et al., 1997). 
Recently, it was shown that in East Asia and in the Western countries, distinct 
variants of H. pylori cagA genes were associated with particular vacA subtypes 
(Van Doom et al, 1999).
However, the association of particular H. pylori genotypes with their 
vimlence for the host is not yet definitely proved. Particularly, the incidence of 
peptic ulcer disease was not reflected in the frequency of different H. pylori 
lineages among different races as Polynesians and European New Zealanders 
(Campbell et al., 1997). Obviously, more studies are needed to compare the 
differences in the H. pylori genome in particular ethnic groups with the same 
underlying disease, living in the same geographic region. Relevant literature 
data are not sufficient and such investigations have not been performed in 
Estonian PPU patients at all.
16
2.4.3. Eradication of H. pylori
The evidence of the role of H. pylori in the pathogenesis of peptic ulcer and its 
eradication therapy have considerably changed the whole peptic ulcer 
management policy. According to the Maastricht Consensus Report 1 from 
1996 (European Helicobacter Pylori Study Group: Current European Concepts 
on the Management of Helicobacter Pylori Infection. The Maastricht Consensus 
Report. 1996) and Maastricht Consensus Report 2 from 2000 (The European 
Helicobacter pylori Study Group, 2000) H. pylori eradication is nowadays 
strongly recommended for all ulcer patients with confirmed infection. Eradi­
cation rates in peroral triple or quadruple regimens exceed 80-90 % in most 
Western studies (Tytgat, 1998; Wermeille et al., 1998). At the same time, 
almost no data are available about the results of such strategy in PPU patients, 
as such patients are mainly excluded from studies. Only preliminary data on 
PPU patients suggest, that H. pylori eradication after simple ulcer suturation 
prevents ulcer recurrence in the subsequent 1-year period (Ng et al., 2000), 
however, published data or long term results on such patients have yet been 
scanty.
Long-term studies conducted in Estonia (follow-up of patients up to 14 years 
after operation) have shown that nearly all gastric mucosa in DU patients is 
affected by H. pylori infection; that vagotomy as an effective method of ulcer 
treatment does not eliminate H. pylori colonization in the stomach, although it 
suppresses temporarily acid production; that the number of recurrent ulcers 
increases steadily with time from operation (Peetsalu et al., 1991; Peetsalu et 
al, 1998).
Therefore, it appears rational to eliminate H. pylori infection in PPU patients 
by using antibacterial treatment immediately after operation in order to decrease 
ulcer recurrence. According to available literature data, such tactics have been 
attempted, and the results have been promising. Friess and coauthors (Friess et 
al, 1992) followed eradication of H. pylori in proximal vagotomy patients after 
a single course of perioperative preventive intravenous antibiotics (Meslocil- 
lin + Metronidazol). After a 3-month follow-up, eradication of H. pylori was 
achieved in 85% of patients. In other reports H. pylori eradication rates in 
nonoperated peptic ulcer bleeding patients ranged from 44% (Sheu et a l, 1999) 
to 87% (Romero et a l, 2000) and were 93% in patients with gastroduodenal 
ulcer disease (Adamek et a l, 1994), with application of intravenous regimens. 
Hence we supposed that it might be advantageous to use clarithromycin 
treatment for eradication of H. pylori infection in our PPU patients immediately 
after operation. Evidently, such treatment tactics cannot be equally effective in 
different countries due to the different antibiotic susceptibility of H. pylori 
strains. As clarithromycin had not been introduced in Estonia before our study, 
one could expect no resistance of H. pylori to this compound. Our aim was to 
find a convenient, efficient and possibly short postoperative H. pylori eradica­
tion regimen for PPU patients.
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The efficiency of different H. pylori eradication regimens for Estonian PPU 
patients has not yet been evaluated.
2.4.4. Failure of H. pylori eradication
There is clear evidence that H. pylori treatment fails in 5% to 20% of the time in 
any regimen used (Tytgat, 1998; Graham et al., 1992). Failure of eradication 
may be related to many reasons or of their combinations.
Noncompliance, often related to side effects, is one of the most important 
reasons for ineffective therapy as pointed out by many researchers (Graham et 
al., 1992; Tylor et al., 1997; Labenz et al., 1995; Qasim et al., 2002). Graham 
and his colleagues found a 30% reduction in efficacy in patients who took less 
than 60% of their medications (Graham et al., 1992).
The efficacy of the treatment of H. pylori infection can be reduced by 
occurrence of primary or acquired resistance to various drugs, especially 
metronidazole (Axon, 1991). In the resistance of metronidazole a significant 
difference was found between the developed and the developing countries 
(Megraud, 1997; Iovene et al., 1999). The rate of resistance to clarithromycin, 
which is another widely used antibiotic for H. pylori eradication, varies from 0- 
15% in Europe and is correlated with the extent of the use of the drug in a 
community (Megraud, 1997; Iovene et al., 1999; Megraud, 1998). In Estonian 
patients studied, 46% (26 of 56) of H. pylori strains were metronidazole 
resistant while all strains were clarithoromycin-sensitive (Lõivukene et al., 
2000). In contrast, H. pylori does not appear to develop significant resistance to 
amoxicillin (Glupczinski et al., 1995) and consumption of antibiotics in 
population is not correlated with the acquired resistance of H. pylori (Lõivukene 
et al., 2002). At the same time, in vitro determined drug resistance is not 
directly correlated with treatment success (Peitz et al., 1999).
Although poor compliance and bacterial resistance are important factors in 
determining treatment success, they cannot explain all failures, suggesting that 
other factors must be involved (Wermeille et al., 2002).
In certain conditions as deficit of nutrients and excess of antibiotics and 
oxygen, etc., H. pylori can form coccoid forms (Donelli et al., 1998; Nakamura 
et al., 2000). The coccoid forms of H. pylori can occur in three states: dead- 
degenerative, viable but not culturable and viable-culturable. Coccoid forms 
play obviously an important role in successful spread of the infection as well as 
in treatment failure (Andersen et al., 2000). During a one-week treatment
H. pylori shifts from the antrum to the corpus and the fundus (Logan et al., 
1995). It is possible that the so-called dormant forms occur extraventricularly as 
well (Atherton et al., 1995).
H. pylori strains are characterised by genetic variability. The patient may be 
colonised by more than one strain (Prewett et al., 1992), which means that there 
may occur competition for localisation and nutrients between different strains.
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In case a treatment resistant strain is accidentally shaded by a treatment sen­
sitive strain and remains thus nonisolated, further treatment may prove 
complicated (Prewett et al., 1992).
Literature provides some evidence that cytotoxic H. pylori cagA positive 
sl/ml or sl/m2 strains respond better to H. pylori eradication therapy compared 
with less cytotoxic cagA negative s2/m2 strains (van Doom et al., 2000; Treiber 
et al., 2002). However, this has not been evaluated in complicated gastric 
diseases as PPU.
Therapy with PPI prior to eradication has been shown to reduce the effi­
ciency of eradication, while pre-treatment with H2 blockers does not influence 
it (Labenz et al., 1995).
Eradication has been reported to be impaired also by smoking (Haruma et 
al., 1999; Labenz et al., 1995; Treiber et al., 2002; Perri et al., 2001), localiza­
tion of the ulcer in the duodenum (Labenz et al., 1995), female sex (Moayyedi 
et al., 1997), younger age of the patient and use of too short regimens (5-7 
days) (Treiber et al., 2002 Labenz et al., 1995).
Different eradication regimens are not equally effective in different regions 
and countries. Unfortunately, good or excellent results obtained from rando­
mized controlled trials do not predict the same rate of effectiveness in general 
practice (Perri et al., 1999). Therefore, the choice of effective eradication 
therapy, suitable for patients with PPU, has not yet been elaborated.
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3. AIMS OF THE STUDY
1. To examine the epidemiology of PPU in a defined area in the southern part 
of Estonia, Tartu county, during the 20-year period from 1981 to 2000.
2. To compare the characteristics of PPU patients and treatment policies, 
complications and outcome of PPU disease in Eastern Europe (including 
Estonia) with respective data from Western countries (Germany).
3. To assess the possible risk factors for high PPU incidence in Estonian 
patients.
4. To evaluate the outcome and possible risk factors for mortality in PPU 
patients with a special reference to the type of operation performed.
5. To determine the prevalence of H. pylori and to compare its genomic 
variation in patients with PPU, living in the same area of Estonia but 
belonging to different nationalities.
6. To compare the distribution of well-known virulence markers (cagA and 
vacA) for H. pylori strains isolated from southern Estonian patients 
suffering from chronic gastritis (CG), peptic ulcer disease (PUD) and 
perforated peptic ulcer (PPU).
7. To evaluate different postoperative H. pylori eradication regimens in PPU 
patients.
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4. PATIENTS AND METHODS
4.1. Subjects
In the presented studies altogether 780 patients were included; 504 PPU patients 
admitted to the Clinic of Surgery of Tartu University Clinics were involved, 129 
of them in prospective studies. There occurred some overlapping between the 
study groups, as in six different studies from 6 to 426 of the PPU patients were 
included (Table 1). In addition, 134 PPU patients from 11 East European 
centres and 37 PPU patients from Germany were analysed. Apart from PPU pa­
tients, also 105 nonoperated patients, among them 36 chronic gastritis patients 
and 69 uncomplicated peptic ulcer patients from Southern Estonia, were 
included in the studies.
Table 1. Catchment of PPU patients in the studies (summarised).
Study type Site Total No. of Goals of the study Publications
Period of data patients (pts. included in part. (No)
collection (males/females) analysis)
1. Retrospective Tartu 426 Epidemiology of PPU Proceedings of
1981-2000 Univ.Clinic (331/95) (426) Eurosurg 2002 (I)
2. Retrospective Tartu Univ. 394 Risk factors for morta­ Hepato-gastro-
1978-1997 Clinic (319/75) lity in PPU (386) enterol(II)
3. Prospective Multicentre 207 1) East European vs
(165/42) German PPU
a) Copernicus 12 East 170* patients (207) Langenbeck’s
1997 European (141/29) 2) risk factors for Arch Surg (III)
Hospitals complications and
b) MEDWIS 11 German 37 mortality in PPU (206)
1994-1996 Hospitals (24/13)
4. Prospective Tartu Univ. 129 1) possible risk factors Eesti Arst (VII)
1997-1999 Clinic (96/33) for high PPU incidence
(129)
2) H.pylori strains in FEMS Microbiol
PPU (51) Lett (IV)
3) eradication of Eesti Arst (VIII)
H.pylori in PPU (49/6) Scand J GE (V)
5. Prospective Tartu Univ. 51 PPU H.pylori strains in PPU, J Clin Microbiol
1995-2000 Clinic 69 PUD PUD and CG patients (VI)
36 CG (156)
includes also 36 PPU patients from Tartu Univ.Clinic
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All 426 patients with PPU, admitted to the Tartu University Clinic from the de­
fined area of Tartu county between 1981 and 2000, were included in a retro­
spective study. The Tartu University Clinic is the only medical institution which 
serves patients with PPU in the area. Tartu county accounts for about one tenth 
of the Estonian population. The population of Tartu county was relatively stable 
during the study period. The estimated mean population was 156,993 (standard 
error ±896 and range 151,010-163,113) throughout the 20-year study period 
according to the Statistical Yearbooks published by the Statistical Office of 
Estonia. No considerable changes took place in the age or sex distribution of the 
population in this period. Incidence of PPU was calculated per 100,000 in­
habitants per year.
Primary data for the identification of patients were obtained from the com­
puterised database of the hospital according to discharge diagnosis. Further, 
case histories and, when needed, also the hospital’s discharge registry and 
logbooks of the operating theatre were studied. No changes took place in 
disease classification during the studied period.
The following information was drawn: patient’s age and sex, previously 
confirmed (endoscopically or on X-ray) ulcer disease, presence of concomitant 
diseases, ulcer location and outcome. Sex and age related analyses were per­
formed on the basis of all patients; the rest of the analyses were carried out 
including only patients with available data. It was impossible to evaluate the 
data on smoking, use of non-steroidal anti- inflammatory drugs and ulcer medi­
cation in the retrospective part of the study on the basis of these documents.
The diagnosis of PPU was confirmed in 426 patients. In 398 patients it was 
confirmed on operation and in four patients on autopsy. Four conservatively 
managed patients were also included in whom all of the following three criteria 
were documented: typical clinical signs, pneumoperitoneum on X-ray and 
endoscopically verified ulcer disease.
To compare the study periods, the patients were divided into two groups ac­
cording to different decades: period I (1981-90) and period П (1991-2000).
The correlation between the annual incidences of PPU in Tartu county and 
the suicide rates in Estonia for 1981-2000 was evaluated using the Pearson 
correlation test. The data of the suicide rates in Estonia were drawn from the 
official database of the Swedish-Estonian Institute of Suicidology.
4.1.1. Retrospective study of the epidemiology of PPU
in Tartu county in 1981-2000.
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In another retrospective study conducted for evaluating the risk factors for 
mortality in PPU patients, using the same methodology, all 394 patients ad­
mitted to the Tartu University Clinic in 1978-97 were included. The following 
data were recorded from case histories and entered into the database: patients’ 
age and sex, previous ulcer history, concomitant diseases, shock on admission 
(systolic blood pressure <100 mmHg), treatment delay, ulcer location, type of 
operation, complications and outcome. Evaluation of the possible risk factors 
for mortality was carried out on 386 out of 394 (i.e. only surgically treated) 
patients using univariate analysis. The analysis involving age, sex and operative 
method was performed on all patients; the other parameters were evaluated on 
available patients. Nonoperatively treated patients were excluded from risk 
stratification. Further multivariate logistic regression was performed to analyse 
the mortality risk factors. Only five significant factors from univariate analysis 
were included in the model.
4.1.2. Retrospective study evaluating the risk factors for mortality in
perforated peptic ulcer patients in Tartu county in 1978-97
4.1.3. Multicentral international prospective studies conducted in 1994-96 
(MEDWIS A 70,Germany) and in 1997 (Copernicus AAP 555, East 
Europe). Comparison of East European and German PPU patients, 
evaluation of the risk factors for complications and mortality
Sixteen centres from nine countries participated in an Eastern European pro­
spective multicentre study of acute abdominal pain (COPERNICUS). Patient 
recruitment took place between 1 January and 31 October 1997, including ulti­
mately 170 patients from 12 centres (incl.36 patients from Tartu) with the final 
diagnosis of PPU. Ten centres from Germany and one from Austria participated 
in a similar study, conducted between October 1994 and March 1996 
(MEDWIS A 70), the final diagnosis of PPU was confirmed in 37 persons. In 
both studies a structured standardised medical history was drawn up for all 
patients and a physical examination was performed according to international 
standards. These clinical findings together with the data of laboratory investi­
gations, ultrasound, x-ray, diagnosis, operative procedure and outcome were 
documented prospectively using a computer program. For documentation, a 
software package with multilingual program versions was developed. For all 
parameters the same standardised definitions were used in both studies. The 
data collected at the centres were transmitted anonymously to the central study 
secretariat in Düsseldorf and were examined with respect to completeness and 
quality. Evaluation of the possible risk factors for complications and mortality 
was carried out on 206 out of 207 patients. One patient dropped out due to 
insufficient data.
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4.1.4. Prospective study conducted at Tartu University Clinic in 1997-1999: 
possible reasons for high PPU incidence in Estonian patients, H. pylori 
strains and postoperative eradication therapy in PPU patients
In a prospective study conducted between 1 January 1997 and 31 December 
1999, all 129 patients with the final diagnosis of PPU, admitted to Tartu 
University Clinic, were included and data were collected according to special 
protocols.
On the basis of this database, the possible risk factors for ongoing high PPU 
incidence in our patients were evaluated.
The presence of H. pylori infection prior to eradication was assessed histo­
logically in nonconsecutive 96 patients of 129 and using PCR technique in 51 
patients of 129; in PCR analysis only the patients whose both parents could be 
identified as being of the same nationality (Estonian or Russian) were included.
Postoperative eradication of H. pylori was attempted in 51 nonconsecutive 
patients of 129, among them two discontinued treatment due to side effects 
(diarrhoea).
4.1.5. Prospective study conducted Tartu University in 1995-2000:
H. pylori in patients with different gastric diseases
In a study carried out at Tartu University Clinics between 1995 and 2000, al­
together 156 patients with 3 different gastric diseases were collected. In 
addition to previously described 51 PPU patients (whose both parents were 
identified as being of the same nationality), also 69 PUD (peptic ulcer disease) 
patients and 36 CG (chronic gastritis) patients referred to the Tartu University 
outpatient clinic for upper gastrointestinal endoscopy from southern Estonia 
were analysed. In the case of CG and PUD, H. pylori strains were isolated from 
gastric mucosal biopsy samples obtained by endoscopy. Endoscopic diagnoses 
were made in 69 cases of PUD (DU in 61 cases and GU in 8 cases). In 36 cases 
without PUD on endoscopy, histologically CG was diagnosed according to the 
Sydney classification (Misiewicz et al., 1990). From the 51 PPU patients, 
gastric specimens of the antral mucosa were obtained for PCR analysis intra- 
operatively or postoperatively by panendoscopy.
4.2. Definitions and terminology: PPU, classification 
of ulcer locations, ulcerogenic drugs, operations and mortality
The diagnosis of PPU was confirmed on operation or autopsy; conservatively 
managed patients were also included if all of the following three criteria were 
documented: typical clinical signs, pneumoperitoneum on X-ray and endosco­
pically verified ulcer disease prior to perforation.
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The ulcers were classified into gastric (GU) and duodenal ulcers (DU) 
according to the site, while DU comprised prepyloric (within 0.5-2.0 cm from 
the pyloric ring), pyloric and bulbar ulcers, as described earlier by Horowitz 
(Horowitz et al., 1989).
Ulcerogenic drugs included NSAIDs and glycocorticoids.
Nondefinitive operations included ulcer excision or suturation. Definitive 
operations included truncal vagotomy combined with pyloroplasty or 
antrumectomy, selective proximal vagotomy with ulcer excision or suturation, 
and partial gastrectomy.
Mortality was assessed during the time the patient remained in hospital, 
irrespective of the 30-day period.
4.3. Determination of H. pylori infection 
in the gastric mucosa
4.3.1. Use of histological method
Biopsy specimens were taken intraoperatively through the ulcer perforation 
using biopsy forceps. Two-three months after the patient finished H. pylori 
eradication therapy specimens were collected on panendoscopy. In both cases 
two specimens from the gastric corpus and two from the antrum were collected 
and fixed in neutral buffered formalin solution and embedded in paraffin. H. 
pylori was later determined semiquantitatively after staining the tissue sections 
by the modified Giemsa method as in earlier studies (Peetsalu et al., 1991). A 
blind examination of all specimens was performed, two from the corpus and 
two from the antrum. The amount of H. pylori was estimated semiquantitatively 
(Stolte et al., 1989). If H. pylori colonisation was patchy, the grade was 
classified according to the most pronounced colonisation. When evaluating the 
presence of bacteria prior to eradication, or the results of H. pylori eradication, 
the patient was considered H. pylori positive in all cases if the bacteria were 
found at least in one specimen of the four. The histological evaluation of the 
specimens was performed by Margot Peetsalu within cooperative research.
4.3.2. Use of PCR method
For isolation of H. pylori, the biopsy samples from patients with CG and PUD 
were placed into Stuart Transport Medium and taken to the laboratory within 
2h. The gastric specimens of the antral mucosa of the 53 PPU patients were 
taken intraoperatively or postoperatively on panendoscopy: these biopsy 
samples were placed directly into the lysis buffer (200 mM Tris-HCl [pH 8.0],
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25 mM EDTA, 300 mM NaCl, 1.2% sodium dodecyl sulfate) and stored at
-20°C.
Further the samples were processed and DNA was extracted as described in 
detail in publications IV and VI (Sillakivi et al., 2001; Andreson et al., 2002). 
For analysis of the s and m regions of vacA and for detection of the cagA gene, 
the primers shown in the Table (Table 1 in publication IV, FEMS Microbiol 
Letters, 2001; 195: page 30) were used. The PCR analyses were performed by 
Helena Andreson within cooperative research.
4.4. Eradication regimens for H. pylori
Six different regimens were used postoperatively. There were five peroral 7- 
days regimens (groups A-E), beginning from the 7th-10 th postoperative day (i.e. 
outpatients), and one intravenous 5-day regimen (group F), beginning from the 
first postoperatiive day (i.e. inpatients).
The use of regimens was changed stepwise with the aim to find a simple, 
effective regimen. In 1997 we started with a classical combination (amoxicillin, 
metronidazole, omeprazole) favoured in Estonia at that time. After unsuccessful 
results clarithromycin monotherapies were initiated in 1998. However, as the 
results were still unsatisfactory, the next combination, advocated by the Esto­
nian Gastroenterologists’ Guideline, combining amoxicillin, clarithromycin and 
omeprazole, was started in 1998.
For nonvagotomized patients two “classical” 7-day peroral triple therapies 
were used:
• Group A — amoxicillin-rat. 1000mg b.i.d + metronidazole 500mg q.i.d. + 
omeprazole (Losec) 20mg b.i.d.
• Group В —  amoxicillin-rat. lOOOmg b.i.d + clarithromycin (Klacid) 500mg 
b.i.d. + omeprazole (Losec) 20mg b.i.d.
The rest of the regimens were modified.
For vagotomized patients the modifications of these previously described 
regimens, excluding proton pump inhibitor (PPI) (Losec), were used with the 
aim to evaluate the hypothesis that vagotomy replaces PPI in such cases:
• Group С — amoxicillin-rat. lOOOmg b.i.d + metronidazole 500mg q.i.d.
• Group D — amoxicillin-rat. lOOOmg b.i.d + clarithromycin (Klacid) 500mg 
b.i.d.
Clarithromycin monotherapy was used both in vagotomized and nonvago­
tomized patients in 1998 when this medicine had not been used in Estonia 
previously, and we could expect no H.pylori resistance to this drug:
• Group E —  clarithromycin (Klacid) 500mg b.i.d.
• Group F — clarithromycin (Klacid) 500mg b.i.d. (intravenous!).
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4.5. Statistical analysis
The mean values are presented as the mean ± standard error of the mean and 
were compared with the use of Student’s t-Test. Absolute numbers were 
compared by the means of chi-square test with continuity correction. The 
association between PPU incidences and suicide rates was evaluated using the 
Pearson correlation test. In the Copernicus and MEDWIS studies, medians with 
the percentiles of 25-75 were calculated for age. For continuous variables the 
Mann Whitney-test was employed. Multivariate analysis with stepwise logistic 
regression (BMDP LR) involved variables that proved to be significant in 
univariate analysis using the default values of the program (enter limit: 0.1, 
remove limit: 0.15). Differences were considered statistically significant for p 
values less than 0.05.
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5. RESULTS
5.1. Epidemiology of PPU in Tartu county in 1981—2000 
(publication I)
The incidence of PPU remained between 4 and 12 (mean 7.4±0.9) per 100,000 
inhabitants per year in period I (Figure 1 in publication I, Proceedings of the 
Eurosurgery 2002. Monduzzi Editore. Lisbon (Portugal), June 5-7, 2002: page 
201). In period II there occurred a sharp increase in the incidence (up to 26), 
which did not drop below 14 (mean 20.0±1.3) (pcO.OOl).
The Pearson correlation test revealed a statistically significant correlation 
between the annual incidences of PPU and the suicide rates in the period 1981— 
2000 (r=0.633, p=0.0027).
An increasing tendency of PPU incidence was similar both for male and 
female patients, while the female:male ratio (1:4.1 in period I and 1:3.3 in 
period II) did not reveal any significant changes (p=ns).
Mean age was almost the same, 47.4±1.7 years in 1981-90 and 46.4±1.1 
years in 1991-2000 (p=ns). The mean age of women, 62.2±2.0 years, exceeded 
significantly that of men, 42.3±0.9 (pcO.OOl). Mean age for GU perforations 
was 56.9±2.3 years and for DU perforations 45.0±1.0 years (pcO.OOl).
GU perforations accounted for 11.1% (13/113) and 11.9% (37/304) of all 
perforations in periods I and II, respectively (p=ns). For female patients GU 
perforations constituted 18.5% (17/92) of all perforations, exceeding the 
respective figure for males, 10.5% (34/325) (p<0.05). In patients aged >65 years 
the proportion of GU perforations was higher, 22.1% (17/77), compared with 
patients aged <65 years, 10.0% (34/340) (p<0.01).
Of the patients 30.4% (112/369) had a history’ of confirmed ulcer disease 
before perforation and 23.4% (94/402) had concomitant diseases.
Twenty-five patients (5.9%) of 426 with PPU died during 1981-2000. Mor­
tality in PPU patients remained almost the same, 6.0% (7/117) in period I and 
5.8% (18/309) in period П (p=ns). Mortality for females was 15.8% versus 
3.0% for males (p<0.001). However, it revealed no significant difference when 
different age groups were compared: 24.2% (8/33) for males and 27.1% (13/48) 
for females, both aged >65, and 0.7% (2/298) for males and 4.3% (2/47) for 
females, both aged <65. The mean age of patients who died, 74.2±2.5 years, 
exceeded significantly that of patients who survived, 45.0±0.9 years (p<0.001).
5.2. Comparison of East European and German PPU patients: 
epidemiology, treatment strategies and outcome 
(publication III)
Among the 170 East European patients with PPU, male patients dominated over 
females with a ratio of 4.9:1, while among the 37 German patients, the male to
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female ratio was only 1.8:1 (Table 1 in publication III, Langenbeck’s Arch 
Surg, 2000; 385: page 345) (p<0.05). Median age was 43.0 (33.0-55.3) years 
for the East European patients and 49.0 (32.0-73.0) years for the German 
patients (p=n.s.); however, it was 53.0 (40.5-71.5) years for female patients in 
the East European study and 73.0 (55.0-82.0) years for female patients in the 
German study (p<0.05). There was a significant difference in ulcer location 
between the studies, gastric ulcer perforations accounting for 23.5% (40 of 170) 
in the East European study and 54.1% (20 of 37) in the German study 
(pcO.OOl). Comparison of the two studies revealed no significant differences in 
delay on admission, shock on admission, previous dyspepsia, previously 
diagnosed ulcer or use of ulcerogenic drugs.
The distribution of operations performed in PPU patients is shown in Table 
(Table 2 in publication HI, Langenbeck’s Arch Surg, 2000; 385: page 346). In 
the German study only 5 (16.1%) patients were operated using a definitive 
method, while in the East European study 67 (41.1%) of the patients underwent 
a definitive operation (p<0.01). In the German study no vagotomies were 
performed for PPU.
There were no significant differences in the overall complication rate, but 
35.1% (13 of 37) of the German patients had general complications compared 
with 12.4% (21 of 169) of the East European patients (Table 3 in publication 
No III, Langenbeck’s Arch Surg, 2000; 385: page 346).
In the East European study 2.4% (4 of 170) of the patients and in the German 
study 13.5% (5 of 37) of the patients died (pcO.Ol). Among these 9 patients there 
were 4 males and 5 females with a median age of 80 years (range 65-93).
5.3. Evaluation of risk factors for complications and 
mortality in PPU patients
The results of univariate analysis for the risk factors for complications and 
mortality (prospective multicentre studies, i.e. Copernicus and MEDWIS, pub­
lication ПГ) are given in Table (Table 4 in publication 1П, Langenbeck’s Arch 
Surg, 2000; 385: page 346) and for mortality (a retrospective Estonian study, 
publication II) are given in Table (Table 5 in publication П, Hepato- 
gastroenterol, 2000; 47: page 1767). Three variables, age > 60 years (PcO.OOl), 
delay on admission >12 hours (pcO.Ol) and female sex (pc0.05) were the signi­
ficant predictors for complications and mortality in the international study; five 
variables, age >65 years, female sex, treatment delay >12 hours, concomitant 
diseases and nondefinitive operation increased mortality risk on the basis of 
univariate analysis in the Estonian study. On the inclusion of these significant 
variables in multivariate analysis with a stepwise logistic regression, only age >60 
years (OR 4.5, p=0.001) and delay on admission >12 hours (OR 2.5, p=0.012) in 
the international study, and only patients’ age >65 years (OR 13.9, p=0.01) and
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concomitant diseases (OR 10.7, p=0.01) in the Estonian study remained the 
significant (independent) predictors for complications and mortality in PPU 
patients.
5.4. Characteristics of PPU patients in a prospective study, 
possible reasons for high PPU incidence in Estonian patients 
(publication VII)
Altogether 129 PPU patients with a mean age of 48.6 years (96 males with a 
mean age of 42.8 and 33 females with a mean age of 65.6 years) were hos­
pitalised at Tartu University Clinic in 1997-99. There were 111 DU and 16 GU 
perforations. Of the patients 30% had a history of confirmed ulcer disease 
before perforation (the diagnosis was confirmed endoscopically in 12%, on X- 
ray in 4%, with both methods in 12% and on a previous operation for 
perforation in 2% of the patients). The time interval from the primary diagnosis 
of ulcer disease till perforation varied from 2 months to 45 years (median 8 
years). At the same time, 78% of all PPU patients and 44% of the patients with 
confirmed ulcer disease had not used any antiulcerogenic drugs during the 
previous year (Table 2), only 1 patient (3%) had used omeprazole and none of 
the 129 patients had received H.pylori eradication treatment. Of the patients 
11% used NSAIDs daily (Table 2), 77% were smokers and 63% complained of 
elevated stress in everyday life (patients' subjective estimation). Of the patients 
24% were pensioners, 41% had employment and 20% were unemployed or had 
only odd-jobs.
Table 2. Characteristics of 129 PPU patients hospitalised to Tartu University Hospital 
in 1997-1999.
Characteristic % Characteristic %
1. Previous history 4. NSAIDs:
-  confirmed ulcer 30% -  daily 11%
-  previous dyspeptic complaints 53% -  sometimes 25%
-  no complaints 17%
2. Antiulcer drugs usage (all patients): 5. Smoking 77%
-  H2 blockers 21% 6. Increased stress in history 63%
-PPI 1%
-  H. pylori eradication 0%
-  without any treatment 78%
3. Antiulcer drugs before perforation 7. Social status:
(patients with confirmed ulcer): -  employed 41%
-PPI 3% -  unemployed/odd-job 20%
-  H2 blocker, maintenance 5% -  pensioner 24%
-  H2 blocker, intermittent 24% -  disabled person 10%
-  H2 blocker, when needed 24% -  student/on maintenance 5%
-  without any treatment 44%
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5.5. H. pylori in PPU patients
5.5.1. H. pylori infection rates in PPU patients
Presence of H. pylori in at least one gastric mucosal specimen out of four 
studied prior to eradication therapy was confirmed in 97% (93 of 96) of patients 
histologically. The bacteria were detected in the antral mucosa in 96% (51 of 
53) of the patients using the PCR technique, while H. pylori was detected 
histologically in the antral mucosa of 52 out of 53 of these PPU patients. Thus 
in one patient with no detected vacA or cagA genotype, H. pylori was still 
proved to be present histologically.
5.5.2. Evaluation of different H. pylori strains in the Estonian and 
Russian patients (publication IV)
In one Estonian male with a cagA positive sample, two vacA gene subtypes 
(sla/m l and sla/m2) were found simultaneously and the patient was excluded 
from further analysis. The distribution of the remaining 50 H. pylori positive 
samples according to the markers of cagA and vacA gene subtypes is presented 
in Table (Table 2 in publication IV, FEMS Microbiol Letters, 2001; 195: page 
31). Among the H. pylori positive samples, 41 (82%) were cagA positive. The 
most frequent was the sla/m l vacA subtype (31 cases), while the s ib  subtype 
was not found in PPU patients from South Estonia.
Both si subtypes (sia/m l and sla/m2) prevailed (98%) in cagA positive 
samples. Comparison of the distribution of the pattern of the three vac A 
subtypes in patients with cagA positive and negative strains by using Chi-square 
test yielded a statistical difference at the level pcO.OOl (Table 2 in publication 
IV, FEMS Microbiol Letters, 2001; 195: page 31).
No differences were observed in the distribution of cagA positive or negative 
markers between the Estonian and Russian patients with PPU, as the cagA gene 
was revealed in 81% (26 of 32) and 83% (15 of 18) of cases, respectively 
(Figure 1 in publication IV, FEMS Microbiol Letters, 2001; 195: page 31). In 
contrast, the distribution of vacA subtypes was different in the gastric samples 
of the Estonian and Russian patients studied. The sla/m l subtype was found in 
75% (24 of 32) of the Estonians but in only 44% (8 of 18) of the Russians. At 
the same time, the sla/m2 subtype was more frequent in the Russians (44%, 
8 cases) than in the Estonians (13%, 4 cases). The s2/m2 subtype was detected 
in 4 (13%) Estonians and 2 (11%) Russians. Comparison of the distribution of 
the three vacA subtypes in the gastric mucosa samples of PPU patients of diffe­
rent nationalities by Chi-square test yielded a statistical difference (p=0.037).
No significant differences were revealed in the distribution of age, sex, 
smoking habits or ulcer location among the Estonian and Russian PPU patients 
studied.
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5.5.3. Results of H. pylori eradication in PPU patients 
(publications No 5 and No 8)
The results of postoperative H. pylori eradication in 49 PPU patients (6 re­
gimens) are presented in Table 3. In different regimens H. pylori was era­
dicated (histological estimation) in 0-37.5% of the patients, while in control 
group of PPU patients (no eradication attempted, i.e. only H-2 blocker or PPI 
was used) eradication was not observed in any patient.
Table 3. The results of postoperative H. pylori eradication after 2 months (histo­
logically) in 49 PPU patients.
Regimen No. of Mean age Males/ Duodenal/ Eradication
patients (years) females gastric ulcer No. of pts. (%)
ACO* 11 40,0 11/0 9/2 2(18,2%)p/o 7 days
AMO* 
p/o 7 days 8 31,9 8/0 8/0 3 (37,5%)
AM** 4 (25,0%)p/o 7 days 16 46,2 15/1 16/0
AC** 1 (16,7%)p/o 7 days 6 37,7 5/1 6/0
Q ***
i/v 5 days 6 54,0 5/1 5/1 0 (0%)
(2 ***
p/o 7 days 2 54,0 1/1 1/1 0 (0%)
No eradication*** 10 46,1 8/2 6/4 0 (0%)
A -  Amoxicillin — rat. lg b.i.d 
С -  Clarithromycin (Klacid) 0.5 g b.i.d 
M -  Metronidazole 0.5 g q.i.d.
О -  Omeprazole (Losec) 20 mg b.i.d
* -  used only in nonvagotomised patients
**-AM and AC (i.e. without PPI) regimens used only in vagotomised patients 
***- both vagotomised and nonvagotomised patients
5.6. H. pylori in patients with different gastric diseases: 
perforated peptic ulcer, peptic ulcer disease and 
chronic gastritis (publication VI)
Among the 156 patients infected with H. pylori strains, no sib  strains were 
found. Multiple H. pylori strains were detected in 5 (3.2%) of the 156 patients 
studied. Among the 151 remaining investigated samples the cagA gene was 
detected in 132 samples of 151 (87%). The relationship between cagA status,
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vacA subtypes and patient’s disease is shown in Table (Table 2 in publication 
VI, J Clin Microbiol, 2002; 40: page 299). In CG and PUD patients all cagA- 
negative isolates were associated with the s2/m2 genotype. In contrast, in the 
PPU group, 4 cagA-negative isolates exhibited the vac A genotype sla  and, 
conversely, one cagA-positive isolate exhibited the vacA genotype s2. However, 
statistically the PPU group did not differ from the CG and PUD groups 
(p>0.05), as a similar correlation was found between cagA-positivity and the 
vac A s la  type.
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6. DISCUSSION
6.1. Epidemiology of PPU in Tartu county in 1981-2000
A sharp, 2.7-fold increase in PPU incidence was noted in Tartu in 1991-2000 
compared with 1981-1990. The PPU incidence of 20.0 for the period 1991— 
2000 is at least 2-3 times as high as that reported from the Western countries, 
2.3-10 (Aeberhard et al., 1990; Hermansson et al., 1997; Makela et al., 1992). 
There were no considerable changes in the Estonian patients’ mean age and sex 
distribution throughout the 20 years. However, the mean age of the studied 
patients was considerably lower (46.7 years vs 53-63 years) and the proportion 
of female patients (22.3% versus about 40-60%) lower compared with the 
figures given in most Western studies (Svanes et al., 1993; Hermansson et al., 
1997; Makela et al., 1992; Gunshefski et al., 1990).
We consider that factors as social stress, low anti-ulcer drug usage, but 
possibly also specific smoking habits and high H. pylori infection rates in 
Estonian community could have a certain impact on such sharp increase in PPU 
incidence.
The role of stress factors has been associated with the rise of PPU incidence 
(Lam et al., 1995). An increased frequency of ulcer perforations has been 
associated with acute society stress as occurring during air-raids in the UK in 
World War II (Jamieson, 1955; Stewart, 1942) and among prisoners-of-war 
captured during that time (Cleave, 1962). Lam et al. (1995) found a relationship 
between the increase in PPU and society stress when Hong Kong underwent 
significant socio-economic and political changes in 1962-85. In 1991 indepen­
dence was re-established in Estonia, which led to profound socio-economic 
changes in the whole society: a drastic decline in economy and a fast increase in 
unemployment. Unemployment rate increased rapidly from 0.6% in 1990 to 
7.6% in 1994 and reached 10.0% in 1996 (Statistical Yearbook of Estonia
1999). It is worth noting that the indirect parameters of social stress, e.g. suicide 
rate (Schneider, 1973), showed a similar trend — after a decrease in 1987-1990 
(incidence 24.5-27.1) suicide rate has risen rapidly in Estonia since 1991 to 
attain the highest figures of the last century (incidence 41.0 in 1994) (Wasser- 
man et al., 1994).
The hypothesis of the role of social stress is also strongly supported by the 
occurrence of a positive correlation between PPU incidence and suicide rate in 
Estonia for 1981-2000. In both samples male patients dominated over females 
(male to female ratios for PPU patients were 4.1 and 3.3, and for suicide victims 
3.5 and 4.5 for 1981-90 and 1991-2000, respectively).
Another point for discussion is use of anti-peptic-ulcer drugs. H2 blockers 
and proton pump inhibitors were introduced later in our community than in 
most developed European countries. Use of modem anti-ulcer drugs in Estonia 
per capita was several times lower than in Stockholm county, Sweden, whereas
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the number of operations for ulcer disease per capita in Estonia was almost 20 
times higher in 1993-1995 (Kiivet et al., 1998). Tbere is evidence that smoking 
plays an important role in ulcer perforation, especially in younger patients 
(Svanes et al., 1997). Although corresponding data were not available for all 
patients of this study, our prospective study has shown that 77% of the PPU 
patients from the same area were daily smokers in 1997-1999 (Sillakivi et al.,
2000). At the same time, the proportion of daily smokers in general adult 
population was only 29-36% in the period 1990-2000, being 42-52% for males 
and 15-23% for females (Kasmel et al., 2001).
The role of the important aetiological factor of peptic ulcer, H. pylori, has 
remained controversial in PPU (Sebastian et al., 1995; Reinbach et al., 1993). 
There were no data for H. pylori infection in the PPU patients studied, but its 
prevalence in Estonia is higher than in the Western countries, affecting 78-87% 
of population in Southern Estonia (Maaroos, 1995; Vorobjova et al., 1994). In 
the same geographical area the prevalence of H. pylori infection was found to 
be 93% in non-operated DU patients (Peetsalu et al., 1991) and 97% in GU 
patients (Maaroos et al., 1991). In a prospective study genotyping H. pylori 
strains, the bacteria were detected in 98% of the PPU patients from the same 
area studied in 1997-1999 (Sillakivi et al., 2001).
Mortality of PPU patients in our study (mean 5.9% for 20 years) was consi­
derably lower than in most recent studies (Hermansson et al., 1997; Gunshefski 
et al., 1990; Hamby et al., 1993). Also, mortality rate did not change during the 
study period, differently from increasing trends established in Western studies 
(Svanes et al., 1993; Gunshefski et al., 1990). The lower mortality can be 
related mainly to the different (i.e. younger) structure of the studied PPU patient 
sample which did not reveal any increase in age.
In conclusion, a significant, 2.7-fold increase in PPU incidence occurred in 
Tartu county since 1991, while the annual incidences of PPU were statistically 
correlated with the suicide rates for the period 1981-2000. At the same time, the 
mean age and sex distribution of PPU patients as well as outcome did not 
display any change.
6.2. Comparison of the East European and German PPU 
patients: epidemiology, treatment strategies and outcome
Within two multicentre prospective studies, conducted at 12 centres in Eastern 
Europe and 11 centres in Germany and Austria, data were collected according 
to standardised forms, which allowed to compare the research results. Of all the 
studied patients with acute abdominal pain, 4.2% in Eastern Europe and 1.6% in 
Germany had the final diagnosis of PPU, which is comparable to the figures of 
several previously reported series (Ikonen et al., 1983, De Dombal, 1988, Oh- 
mann et al., 1992).
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The main distinctive characteristics of the PPU patients in the two studies 
were sex and ulcer localisation. The proportion of females among the German 
patients was 35.1% versus 17.1% among the East European patients, and the 
proportion of gastric ulcer perforations was 54.1% versus 23.5%. In the German 
study the proportion of females is closer to the figures reported from the 
Western countries in recent decades, 40-60% (Aeberhard et al., 1990; Svanes et 
al., 1993; Mäkela et al., 1992; Hermansson et al., 1997), while the respective 
proportion for Eastern Europe is clearly divergent. The higher proportion of 
gastric ulcers in the German study is in agreement with data indicating its 
increasing trend in Western patients (Aeberhard et al., 1990; Svanes et al.,
1993).
Median age did not reveal any significant difference, being 43 years for the 
Copernicus patients and 49 years for the MEDWIS patients. Both figures are 
lower than the reported median age of 62-66 years (Svanes et al., 1993; Her­
mansson et al., 1997). However, the higher median age of the German female 
patients compared with that of their East European counterparts (73 years 
versus 53 years) can be explained by the above described trends in the Western 
countries.
The other variables, i.e. delay on admission, shock on admission and pre­
viously proved ulcer disease, did not reveal differences between the East Euro­
pean and the German patients. There were relatively few users of ulcerogenic 
drugs in either study (8.1% and 18.8%) compared with the reported proportion 
of 40-70% (Bulut et al., 1996; Bliss et al., 1991; Lanas et al., 1997; Svanes et 
al., 1996).
The distribution of different operations in both studies was quite different, 
definitive operations accounting for 16.1% in the German study and 41.1% in 
the East European study. At different East European hospitals the proportion of 
definitive surgery varied in the range 0-91%, while at five centres only non­
definitive operations were used. At the same time, in the German study, among 
definitive operations only 5 gastric resections were performed, whereas in the 
Eastern Europe, besides 12 gastric resections, also 55 operations combined with 
vagotomy were used. The high proportion of definitive operations is a charac­
teristic feature of Eastern Europe, while according to the data of recent reports 
from the Western countries the number of definitive procedures is diminishing 
rapidly (Hermansson et al., 1997; Roher et al., 1996; AI Assi et al., 1994; 
Kozol, 1995, Blomgren, 1997). Overall complication rates, 18.3% in the Cope­
rnicus study and 27.0% in the MEDWIS study, did not reveal significant 
differences, however, the proportion of patients with general complications was 
12.4% and 35.1% (P<0.01), respectively. Like the other variables, overall 
complication rate in German patients is closer to 30%-57% reported in most 
Western studies (Evans et al., 1997; Gunshefski et al., 1990; Wakayama et al.,
1994), while the figures for Eastern Europe are comparable to that reported by 
Boey, 14% (Boey et al., 1982). Higher figures for general complications in 
German patients can be attributed to the older median age of the patient sample
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of that study. The higher proportion of females with higher median age can play 
some role in the development of general complications, as a trend of increase in 
general complications with the ageing of patients has been brought out in the 
Western countries (Svanes et al., 1993).
Differences in mortality, 13.5% for the MEDWIS patients and 2.4% for the 
Copernicus patients, can also be explained by the different age structure of the 
two patient samples. All patients who died were >65 years old. The mortality 
rate of 13.5% in the MEDWIS study was comparable to 16-31% reported from 
the Western countries in the 1990s (Bulut et al., 1996; Hermansson et al., 1997; 
Evans et al., 1997), while the rate of 2.4% for the East European patients was 
significantly lower.
6.3. Evaluation of the risk factors for complications and 
mortality in PPU patients
Optimal management of patients with PPU is still a matter of discussion. 
Decrease in mortality rates, from 20-30% in the 1930s-1940s (18) to about 5 - 
10% in the 1970s (Svanes et al., 1993; Boey et al., 1982; Mattingly et al.,
1980), was not observed in the 1980s-1990s (Svanes et al., 1993; Horowitz et 
al., 1989). Moreover, mortality figures as high as 17-31% can be found in the 
literature (Hermansson et al., 1997; Hamby et al., 1993; Bulut et al., 1996; Irvin 
et al., 1989). Svanes et al found that the increasing mean age of patients may 
conceal better results in the management of PPU patients, and hence mortality 
figures do not increase when adjusting to age groups (Svanes et al., 1989).
There has been much discussion about the choice of surgical procedure in 
the case of emergency operation. In our study 245 nondefinitive operations with 
a mortality of 7.3% and 141 definitive operations with a mortality of 1.4% were 
performed. However, comparison of the patients of the two groups (Table 4 in 
publication II, Hepato-gastroenterol, 2000; 47: page 1767). revealed that the 
higher mortality rates for nondefinitive operations resulted from the effect of the 
surgeon’s decision on the choice of operation. Patients with probable risk 
factors served as more eligible candidates for nondefinitive procedure, since it 
was thought to be safer. Our results of multifactorial analysis revealed that 
operative method had no independent effect on mortality. Numerous data give 
evidence of better long-term results after definitive operation: recurrence rate is 
lower and the patient’s self-estimation of his/her condition is higher (Jordan et 
al., 1995; Robles et al., 1995; Peetsalu et al., 1994). Several studies have con­
firmed that there is no reason to fear for higher mortality in an emergency 
situation when definitive procedures are applied (Gunshefski et al., 1990; 
Hamby et al., 1993; Welch et al., 1986; McIntosh et al., 1996); in this respect 
nondefinitive operations appear to have no advantages even in high risk patients
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(Schein et al., 1990; Bennett et al., 1985; DiQuinzio et al., 1992). Our results 
demonstrate agreement with the above investigations.
Different studies have described about ten risk factors predicting outcome 
and morbidity in PPU patients, the most frequent being old age, concomitant 
diseases, treatment delay and shock on admission (Boey et al., 1982; Evans et 
al., 1997; Mattingly et al., 1980; Irvin, 1989; McIntosh et al., 1996; Wakayama 
et al., 1994), but also gastric ulcer location (Hamby et al., 1993; Horowitz et al., 
1989; Svanes et al., 1989), hospitalisation at the time of perforation (Hamby et 
al., 1993), large diameter of perforation (Paunescu et al., 1995), use of steroids 
(Hamby et al., 1993), leukocyte rate lower than 9.500/mm3 (Wakayama et al.,
1994) and reperforation (Evans et al., 1997).
Univariate analysis of our data revealed that high age (>65 years), concomi­
tant diseases, treatment delay >12 hours, female sex and nondefinitive operation 
are the risk factors for mortality, whereas location of ulcer, shock on admission 
and previous ulcer history had no influence on mortality in the Estonian study. 
However, only high age and concomitant diseases remained significant in 
multivariate analysis. Apart from nondefinitive surgery discussed above, neither 
treatment delay nor female sex had an independent effect on mortality in 
multifactorial analysis.
In univariate analysis of the international study, age >60 years, delayed treat­
ment >12 hours and female sex were significant in the development of compli­
cations, while in multivariate analysis, only high age and delayed treatment 
remained the independent predictors for complications. Complications were 
related neither to ulcer location nor to the operation method applied.
Wakayama et al. concluded that old age alone contributed to lethal outcome 
(Wakayama et al., 1994), while others found that old age alone (without con­
current factors) did not predict outcome (Boey et al., 1982, Evans et al., 1997). 
Our results are in accordance with the studies where old age per se was found to 
predict outcome.
In conclusion, patients’ high age and presence of concomitant diseases pre­
dicted outcome after surgical procedure performed for PPU. The complications 
were related to patients high age and treatment delay. The result did not depend 
on the fact whether definitive or nondefinitive operations were applied.
6.4. Characteristics of PPU patients in a prospective study: 
possible reasons for high PPU incidence in the patients
As in our retrospective study (Sillakivi et al., 2002) the patients of this study 
were significantly younger, mean age 48 years vs 53-63 years in Western 
studies, and the proportion of women was smaller, 26% vs 40-69% in Western 
studies, than in most studies conducted in developed countries (Svanes et al., 
1993; Aeberhard et al., 1990; Hermansson et al., 1997; Hamby et al., 1993).
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However, the age and sex composition of the Estonian PPU patients were simi­
lar to that of the patients studied in 1997 in East European countries (Coper­
nicus Programme: a study of acute abdominal pain performed in East Europe) 
(Sillakivi et al., 2000).
The results of this study point to several factors the co-effect of which has 
obviously resulted in the sharp increase in PPU incidence during the last decade 
in comparison with developed countries:
1. The role of social stress: the sharp rise in the curve of PPU incidence since 
1991 is similar to the rise in the curve of suicide incidence (Wasserman et 
al, 1994). An analogous significant rise in PPU incidence was also noted in 
Hong Kong in the period after the establishment of independence, when a 
significant increase in stress was recorded against the background of 
political-economic changes (Lam et al., 1995).
2. Social factors: the number of representatives of the so-called lower social 
class among the patients was large (only 41% had steady job). Duodenal 
ulcer, in particular, has been associated with lower social classes (Elashoff 
et al., 1980).
3. A large proportion of smokers among the patients (77%): the important role 
of smoking in development of PPU has also been pointed out in other 
studies (Svanes, 2000).
4. Inadequacy of previous diagnostics: in a very large proportion of the PPU 
patients (70%) ulcer disease had remained undiagnosed, although upper 
abdominal complaints, characteristic of ulcer disease, occurred in 53% of 
the patients. Probable reasons for this are also low disease awareness and 
poorer access to medical aid for some social groups.
5. Non-use of modem conservative ulcer treatment prior to the development of 
perforation: 44% of the patients with diagnosed ulcer disease had not 
received ulcer treatment during a year before perforation. Earlier studies 
have shown that long-term maintenance treatment with H2 blockers reduces 
significantly the risk of perforation in comparison with non-treated ulcer 
patients (Penston, 1990). No patient had undergone H. pylori eradication 
treatment. Comparison of the results of this study with those of the study 
conducted in Estonia in 1995 (Labotkin, 1996) reveals no significant 
change. Also, a questionnaire carried out five years ago demonstrated that 
although 34-84% of the physicians considered maintenance treatment and
H. pylori treatment appropriate, such treatment was mostly administered for 
only 0-20% of the patients. However, it should be noted that the results of 
the earlier study were obtained with the use of a questionnaire for doctors, 
while the results of this study were based on an interview concerning 
actually received treatment.
The results of our study show that the frequency of H. pylori in PPU patients is 
very high (97% vs 50-83% in developed countries) (Reinbach et al., 1993; 
Sebastian et al., 1995). However, it is not clear if the observed changes in PPU
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incidence are also associated with the high H. pylori infection rate of the 
Estonian patients. The role of H. pylori, whose eradication has become a major 
argument in the advance of nondefinitive operative treatment tactics in ulcer 
disease, is not ultimately clear in the case of perforations, unlike it is, e.g. in the 
case of ulcer hemorrhage (Reinbach et al., 1993; Sebastian et al., 1995). 
Furthermore, Arakawa and coauthors consider it appropriate to distinguish, 
besides H. pylori negative ulcer disease, also separate H. pylori-causing ulcer 
and H. pylori-non-causing ulcer in the case of a positive bacterial finding — 
indicating the possibility that namely in populations with high H. pylori 
infection rate a large proportion of ulcer patients infected with the bacterium are 
characterised by the circumstance that application or non-application of 
eradication does not actually influence disease remission or recurrence 
(Arakawa et al., 2000).
In conclusion, it can be said that the incidence of PPU in Estonia in the last 
decade was steadily high. Among different risk factors for the Estonian patients, 
one can bring out high H. pylori incidence (97%), stress, social problems, 
smoking (77% of PPU patients). Ulcer disease was diagnosed in most patients 
(70%) as late as on development of perforation. Nor was adequate modem 
conservative treatment available even for patients with previously diagnosed 
ulcer disease, while H. pylori eradication was not altogether applied in disease 
management.
6.5. H. pylori in PPU patients
6.5.1. Evaluation of different H. pylori strains in the Estonian and 
Russian PPU patients
We investigated the distribution of H. pylori genotypes in Southern Estonia 
among patients with complicated, histologically proven H. pylori associated 
peptic ulcer disease. Using PCR method the genotypes of H. pylori were 
estimated according to the presence of the cagA gene and vacA gene subtypes in 
specimens of the gastric antral mucosa.
That fact that we did not find any gastric mucosa sample containing the sib 
subtype of the vacA gene among the 50 PPU patients investigated by us 
confirms the existence of geographical differences between the H. pylori 
genotypes. And, although the sib  subtype was not found in the H. pylori of 
Asian patients (Atherton et al., 1996), its presence has been established in 
several studies conducted in Portugal, the Netherlands, and the USA (Atherton 
et al., 1997; Campbell et al., 1997; Pan et al., 1999). However, as Estonia is 
situated in Eastern Europe, geographic differences between the H. pylori 
genotypes cannot be linked with different continents.
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Furthermore, in our study the distribution of the sla/m l, sla/m2 and s2/m2 
subtypes of vacA genes was statistically different in the Estonian and Russian 
patients (p<0.05), both groups living in South Estonia. This confirms data about 
the ethnic tropism of H. pylori, suggested by Campbell et al. (Campbell et al.,
1997). Yet these authors associated the differences between the H. pylori 
strains, colonising Polynesians and Europeans in New Zealand, with race- 
specific specialisation of H. pylori separate strains. However, this cannot be the 
reason for H. pylori related ethnic differences between Estonians and Russians, 
as both nationalities belong to the same race. We suppose that different pre­
dominant strains may be circulating among different ethnic groups in a 
particular area.
The Estonian and Russian PPU patients studied by us showed a similarity in 
the distribution of age, sex and smoking habits as well as ulcer localisation. 
Evidently, these factors are not closely associated with the ethnic tropism of H. 
pylori. Regrettably, we could not follow the socio-economic conditions in the 
case of our patients. In previous epidemiological studies these conditions were 
strongly associated with transmission of H. pylori infection. In Germany, H. 
pylori infection was established in 6.1% of native German children versus 
44.8% of Turkish children (Bode et al., 1998). However, the different incidence 
of H. pylori infection in populations living in the same country but having a 
different economic background does not explain the spread of genetically 
distinct H. pylori strains among these populations. Whether the other determi­
nants, e.g. region/country of birth and childhood, or microbial adherence and 
host receptors, determine a particular distribution of different genotypes of H. py­
lori should be established in further studies with a larger number of subjects.
The virulence markers differentiating H. pylori strains in patients with 
complicated and uncomplicated peptic ulcer have not been assessed up to now. 
In our study the cagA gene of the H. pylori genome was found in 82% of PPU 
patients. The cagA status was similar in samples from the Estonian and Russian 
patients with the same underlying disease, while the vac A si subtype prevailed 
in both nationalities (98%). High prevalence of the cagA+ genotype and the 
vacA si subtype has been associated with increased virulence of H. pylori 
strains (Atherton et al., 1995, Atherton et al., 1997). However, recently we 
found a predominance of the vacA si gene in another sample of South-Estonian 
patients suffering either from chronic active gastritis or peptic ulcer disease 
(Lõivukene et al., 2000). It is likely that the presence of cagA and vacA si 
genes of H. pylori strains is not exclusively specific for complicated peptic ulcer 
disease but may merely reflect the circulation of predominant strains in a 
particular geographic region of Estonia, causing severe gastric diseases.
In conclusion, we found geographic and ethnic differences in H. pylori 
among patients with PPU from Estonia. This finding points to the need of 
further investigations aimed at the future development of novel therapeutic 
targets and vaccines specific for different ethnic groups.
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6.5.2. Results of H. pylori eradication in PPU patients
In our study, H. pylori eradication was observed in a considerably smaller 
proportion of the PPU patients than expected and this even with the use of two 
classical triple treatment schemes well known worldwide: scheme I (amoxicil­
lin, chlarithromycin and omeprazole), belonging also to the treatment schemes 
recommended by the Estonian Gastroenterologists’ Society (Labotkin et al.,
1999), yielded a positive eradication result in only 18.2% of the cases; scheme
II (metronidazole, amoxicillin and omeprazole), which yielded a positive result 
in 37.5% of the cases (Table 1). The other modified treatment schemes 
employed by us led to an unsatisfactory result as well — eradication in 0-25% 
of the cases.
Although chlarithromycin monotherapy was unsuccessful, in our opinion, 
the idea of immediate postoperative H. pylori eradication in complicated peptic 
ulcer patients seems to deserve further research, especially when combining 
several antibiotics and acid suppressing compounds.
Why eradication in this study occurred in such a small proportion of the 
patients remains unclear. As the possible reasons, the following circumstances 
can be considered:
1. Weekly peroral treatment courses applied by us for PPU patients in the 
postoperative period, which have yielded positive results in uncomplicated 
ulcer patients in Estonia as well, may not be suitable in PPU, or else the 
patients of this group require a longer treatment course. Yet the combina­
tion amoxicillin + chlarithromycin + omeprazole, used worldwide, belongs 
to the list recommended by the Estonian Gastroenterologists’ Society and 
has yielded 91% eradication in uncomplicated PPU patients (Kolk et al.,
1998).
2. Initiation of treatment on the 7th-10m postoperative day in the PPU patients 
is too early. However, this disagrees with the results of other investigators 
according to which H. pylori treatment already from the 3rd postoperative 
day was successful in 83% of PPU patients (Ng et al., 2000).
3. Problems related to compliance, which has been regarded among the most 
important reasons for H. pylori eradication failure (Freston, 2000). It is 
evident that an outpatient setting does not provide the possibility for direct 
control of the actual use of medicines. However, as the patients studied by 
us attended outpatient follow-up at 2-3 months after the treatment course 
and consented to undergo an inconvenient procedure, endoscopy, it shows 
cooperation on the part of the patients and their interest in H. pylori 
eradication result.
As the reasons for eradication failure, one should also consider the large 
proportion of smokers (77%) among the PPU patients and their low mean age. 
These factors have also been reported to increase eradication failure rates 
(Labenz et al., 1995; Treiber et al., 2002; Haruma et al., 1999)
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The circumstance that according to a PCR study, eradication was observed at
2 months in only 41% (15 of 37) of the PPU patients treated with the use of 
different management schemes, should also be noted (unpublished, MSc thesis 
by H. Andreson).
The results of our study demonstrate that establishment of an effective treat­
ment scheme, suitable for PPU patients, requires further research. Clarification 
of the specificity of H. pylori strains in PPU might offer new solutions for 
treatment problems as well.
Summing up, all treatment schemes used for H. pylori eradication in this 
study, including the combination which is popular worldwide and is currently 
recommended by Estonian gastroenterologists, have not resulted in the expected 
effect in PPU patients. Considering the high PPU incidence and the 97% H. 
pylori infection rate of these patients, elaboration of treatment tactics, suitable 
in the conditions of Estonia, requires further investigations in order to avoid 
postoperative ulcer recurrence and consequent development of life-threatening 
complications.
6.6. H. pylori in patients with different gastric diseases: 
perforated peptic ulcer, uncomplicated peptic ulcer 
disease and chronic gastritis
A study by Vorobjova et al. (Vorobjova et al., 1998) demonstrated a high 
prevalence of cagA in a sample population of Estonian adults (63%) and 
children (46%). We found that the distribution of the cagA gene among the 
large sample of patients with different clinical diagnosis (PPU, PUD, CG) was 
very high (87%). Our study indicates that the cagA gene of H. pylori and its 
defined protein are the important predictors of several gastric diseases, even in 
populations with a high prevalence of infection like Estonia.
According to a large number of studies (Atherton et al., 1995; Atherton et 
al., 1997; Cover et al., 1994; Evans et al., 1998; van Doom et al., 1998), the 
vacA sla/m l subtype is considered more cytotoxic and is therefore more 
strongly related to development of PUD than the sla/m2 and s2/m2 vacA 
genotypes. The s2 strains are rarely associated with peptic ulcer disease and are 
more common in cases of chronic gastritis or non-ulcer dyspepsia (Evans et al., 
1998; Gusmäo et al., 2000; Rudi et al., 1999; Strobel et al., 1998; van Doom et 
al., 1998). In our study there was no difference in colonisation by H. pylori 
cytotoxic strains between the patients with uncomplicated PUD and with PPU.
In conclusion, we established a high prevalence of the cagA gene of H. 
pylori among patients with different gastric diseases. However, no difference 
existed in the distribution of the cagA and vac A genotypes between patients 
with PPU, uncomplicated PUD and chronic gastritis in Estonia. This fact refers 
to the possibility of the clonal spread of a virulent H. pylori strain in Estonia, 
which needs to be elucidated.
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7. CONCLUSIONS
1. A pronounced (2.7-fold) increase in PPU incidence took place in Tartu 
county from the period 1981-90 to 1991-2000, while the annual incidences 
of PPU were significantly correlated with the annual suicide incidences for 
1981-2000. No significant changes were observed in PPU patients’ mean 
age, sex distribution and outcome during the two periods compared. The 
PPU incidence of 20.0 for the period 1991-2000 is at least 2-3 times as 
high as that reported from developed countries.
2. In our studies, Estonian PPU patients were younger, the proportion of 
female patients was lower, and the proportion of definitive operations was 
higher compared with the German study or with reports from developed 
countries. The age and sex distribution of the Estonian patients studied and 
the use of surgical methods in treatment and outcome are similar to those 
observed in the East European study.
3. The high PPU incidence in Tartu county (and in Estonia) in the recent 
decade is evidently related to increased (social) stress, cigarette smoking 
and the lack of modem effective antiulcer therapy for patients with ulcer 
disease. To reduce the incidence of this life-threatening complication, 
proper measures should be directed to the raising of the awareness of both 
the medical staff and the public.
4. Patients’ high age (>65 years) and the presence of concomitant diseases are 
the independent predictors of lethal outcome after surgical procedure 
performed for PPU. Age > 60 years and delay on admission > 1 2  hours are 
the significant predictors for complications in PPU patients. The mortality 
and complication rates are not influenced by the fact whether definitive or 
nondefinitive operation is applied.
5. H. pylori infection is present in 97% of the Estonian PPU patients. H. pylori 
infection is characterized by geographic and ethnic differences among the PPU 
patients: the distribution of the vacA gene subtypes is statistically different in 
the Estonian and Russian patients, and the sib  subtype of the vac A gene which 
is widespread in some other countries, is lacking in our patients. This finding 
points to the need for further investigations aimed at the development of novel 
therapeutic targets and vaccines specific for different ethnic groups.
6. A high (87%) prevalence of the cagA gene of H. pylori is characteristic of 
patients with different gastric diseases from Southern Estonia. The distribu­
tion of the virulence markers, particulary the cagA gene and vacA genotypes, 
is not different for patients with PPU, for those with uncomplicated PUD and 
for those with chronic gastritis in Estonia.
7. The present results of H. pylori eradication in the Estonian PPU patients 
have been unsatisfactory with the use of all studied regimens, indicating 
that PPU cannot be managed using ordinary H. pylori eradication schemes. 
Detailed classification of the reasons for management failure as well as 
development of the treatment tactics suitable for the Estonian conditions 
requires further research.
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SUMMARY IN ESTONIAN
Perforeerunud peptiline haavand Eestis: epidemioloogia, 
riskifaktorid ning seosed Helicobacter pyloriga
Perforeerunud peptilist haavandit (PPH) kirjeldas esmakordselt Crisp juba 1843 
aastal. Sellest ajast on aga PPH epidemioloogias toimunud suured muutused. 
Viimastel aastakümnetel on arenenud riikides PPH esinemissagedus langenud 
noortel patsientidel ja meestel, kuid on tõusnud eakamatel inimestel ja naistel. 
Seejuures on tõusnud PPH patsientide keskmine vanus, naiste osakaal, mitte- 
steroidsete põletiku vastaste ainete tarvitajate osakaal ning kaasuvate haigustega 
patsientide arv.
Kuigi plaaniline kirurgiline ravi haavandtõve puhul on kogu maailmas oluli­
selt langenud tänu uute võimsate ravimite kasutusele võtmisele, pole haavand­
tõve tüsistuste kirurgilise ravi vajadus vähenenud. Vastavalt Sotsiaalministee­
riumi andmetele on Eestis PPH tõttu teostatud erakorraliste operatsioonide arv 
märgatavalt kasvanud alates 1991 aastast.
PPH kirurgilises ravis on toimunud muutused mittedefinitiivsete, haavandi 
patogeneetilisi mehhanisme mittemõjutavate operatsioonide kasuks. Niisugustele 
ravitaktika muutustele on kõige olulisemat mõju avaldanud Helicobacter pylori 
eradikatsiooni postoperatiivne rakendamine. Samas erinevalt näiteks haavandtõve 
teisest tüsistusest, haavandi verejooksust, pole PPH puhul selle ravitaktika 
kaugtulemused erinevate uurijate poolt seni piisavalt tõestatud. Ka H. pylori enese 
roll haavandi perforeerumisel pole üheselt määratletav. Küll on aga kaugtule- 
muste võrdlemine näidanud, et definitiivsete operatsioonimeetodite kasutamisel 
on tulemused paremad kui mittedefinitiivsete meetodite kasutamisel.
Vaatamata meditsiini edusammudele pole ilmnenud ka PPH ravitulemuste 
paranemist, kusjuures surevuse näitajad püsivad endiselt kõrged, seda eriti va­
nemate patsientide puhul. Surevus on seotud peamiselt patsientide vanuse, 
kaasuvate haiguste esinemise ning hilinenud raviga. Viimastes uuringutes pole 
leitud tõestust, et operatsioonimeetodi valik ise mõjutaks surevuse näitajaid.
H. pylori esinemissagedus Eestis (kuni 87% populatsioonist) on oluliselt 
kõrgem kui arenenud riikides (umbes 50%). PPH patsientide puhul kõigub
H. pylori esinemissagedus maailmas väga suurtes piirides (50-97%).
Nüüdseks on üha enam töid suunatud ka H. pylori erinevate tüvede ja nende 
virulentsusmarkerite uurimisele, et selgitada seoseid nende faktorite ja erinevate 
maohaiguste tekke vahel. Seni on erinevates uuringutes leitud seosed sageli 
vastuolulised.
Uurimistöö eesmärgid ja ülesanded
Arvestades asjaolu, et haavandtõve eluohtliku tüsistuse, PPH, esinemissagedus 
Eestis on järsult tõusnud alates 1991 aastast ja  selle haiguse epidemioloogiat,
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aga samuti seoseid PPH ja  H. pylori vahel pole Eestis varem uuritud, püstitati
antud uurimistöös järgmised eesmärgid:
1. Uurida PPH epidemioloogilist olukorda ja  muutusi Tartu piirkonnas 20 
aastase perioodi jooksul (1981-2000).
2. Võrrelda Ida-Euroopa (s.h. Eesti) PPH patsientide vanuselist ja soolist 
koosseisu, tüsistusi ja  ravitulemusi Lääne Euroopa (Saksamaa) PPH patsien­
tide vastavate andmetega.
1. Hinnata jätkuvalt kõrge PPH esinemissageduse püsimise võimalikke põhjusi 
(riskifaktoreid) Eestis.
2. Hinnata riskifaktoreid, mis mõjutavad ravitulemust ja  suremust PPH pat­
sientide puhul, eriti seost ravitulemuse ja kasutatud operatsioonimeetodi 
vahel.
3. Määrata kindlaks H. pylori infektsiooni esinemine ja võrrelda selle bakteri 
genoomi varieeruvust proovides, mis on saadud PPH patsientidelt, kes 
elavad Lõuna-Eestis, kuid kuuluvad erinevatesse rahvustesse (eestlased ja 
venelased).
4. Võrrelda laialdaselt tuntud H. pylori virulentsusmarkerite, cagA ja vacA, 
jaotumust erinevate maohaigustega (krooniline gastriit, peptiline haavand ja 
PPH) Lõuna-Eesti patsientidel.
5. Hinnata erinevate postoperatiivsete H. pylori eradikatsioonile suunatud ravi- 
skeemide efektiivsust Eesti PPH patsientidel.
Uurimistulemused peaksid ühtlasi kaasa aitama teaduspõhiste, Eesti oludele
sobivate efektiivsete PPH ravijuhiste väljatöötamisele.
Uuritav materjal ja meetodid
Antud uuringusse kaasati kokku 780 patsienti. Nende hulgast 504 PPH patsienti 
hospitaliseeriti TÜ Kirurgiakliinikusse aastatel 1978-2000, kellest 129 osalesid 
prospektiivsetes uuringutes. Erinevate alauuringute puhul esines uuri­
misgruppide oluline kattumine, vastavatesse analüüsidesse hõlmatud patsientide 
arv kõikus vahemikus 6 kuni 426. Lisaks nendele uuriti 134 PPH patsienti 11 
Ida-Euroopa keskusest ja  37 Saksamaalt pärit PPH patsienti. Tüsistunud haa­
vandtõvega patsientide kõrval lülitati uuringusse ka 36 kroonilise gastriidi ja 69 
mittetüsistunud haavandtõvega patsienti Lõuna-Eesti regioonist.
Kahes retrospektiivses uuringus, mis käsitlesid PPH epidemioloogiat Tartu 
piirkonnas aastatel 1981-2000 ja surevuse riskifaktoreid kirurgiliselt ravitud 
PPH puhul, uuriti algmaterjalina läbi 1978-2000 aasta haiguslood ning vaja­
dusel ka operatsiooniraamatud ja haigete hospitaliseerimise registreerimisraa­
matud.
Prospektiivsed uuringud viidi läbi aastatel 1995-2000. Seejuures kasutati nii 
spetsiaalseid uurimisprotokolle haigete põhjaliku küsitluse, kliinilise uuringu, 
ravitulemuse jälgimise ja  endoskoopiate läbiviimise kohta kui ka histoloogilisi
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ja molekulaarseid (polümeraasahelreaktsioon) uuringuid H. pylori ja  tema 
virulentsusmarkerite määramiseks.
H. pylori eradikatsiooni üritati postoperatiivselt nii klassikaliste suukaudsete 
raviskeemide kui ka modifitseeritud, sealhulgas intravenoossete, raviskeemide 
abil. Eradikatsiooni läbinud patsiendid hõlmati 2 kuu möödumisel ravist 
järelkontrollidesse, mille käigus kasutati endoskoopilisi, histoloogilisi ja 
molekulaarseid uuringuid.
Kõikidel juhtudel sisestati andmed enne analüüsimist arvutiandmebaasi­
desse.
Uurimistööst tulenevad järeldused
1. Järsk, 2,7 kordne PPH esinemissageduse tõus leidis aset Tartu piirkonnas 
perioodil 1991-2000 võrreldes perioodiga 1981-1990, kusjuures PPH iga- 
aastased esinemissagedused aastatel 1981-2000 korreleerusid iga-aastaste 
suitsiidikordajatega samal perioodil. Perioodide võrdlusel ei täheldatud 
olulisi muutusi PPH patsientide vanuselises ega soolises koosseisus ega ka 
surevuses. PPH keskmine esinemissagedus perioodil 1991-2000 (20.0) 
ületab vähemalt 2-3 korda arenenud riikide vastava näitaja.
2. Uuritud Eesti PPH patsiendid olid nooremad, naiste osakaal väiksem ja 
definitiivsete operatsioonimeetodite kasutamine sagedasem kui Saksamaal 
või teistes arenenud riikides läbiviidud uuringute puhul. Samas Eesti PPH 
patsientide vanuseline ja sooline jaotumus, kirurgiliste meetodite kasuta­
mine ja suremus olid samased Ida-Euroopas läbiviidud uuringute vastavate 
näitajatega.
3. PPH kõrget esinemissagedust Eestis alates 1991. aastast võib seostada kõr­
genenud (sotsiaalse) stressi ja suitsetamisega ning kaasaegse adekvaatse 
medikamentoosse ravi mittekasutamisega haavandtõvega haigetel. Et 
vähendada peptilise haavandi eluohtliku tüsistuse, perforatsiooni, teket, 
võiksid meetmed olukorra parandamiseks olla suunatud nii arstkonnale kui 
ka selgitustöö tõhustamisele elanikkonna seas.
4. Patsientide kõrge iga ja  kaasuvate haiguste esinemine osutusid iseseis­
vateks surevust mõjutavateks faktoriteks PPH patsientide kirurgilise ravi 
korral. Vanus > 60 aastat ja  >12 tunni möödumine perforatsioonist enne 
ravi alustamist olid olulisteks tüsistuste teket määravateks faktoriteks. 
Tüsistused ja suremus ei sõltunud sellest, kas kasutati definitiivseid või 
mittedefinitiivseid operatsioonimeetodeid.
5. H. pylori infektsioon esines 97% Eesti PPH patsientidest. Lõuna-Eesti PPH 
patsientide H pylori tüvede puhul ilmnesid geograafilised ja etnilised 
erinevused: vacA geeni alatüüpide jaotumus oli statistiliselt erinev eesti ja 
vene rahvusest patsientidelt isoleeritud proovides; kusjuures vacA geeni 
s lb  alatüüpi, mis on mõnedes riikides laialdaselt levinud, ei leitud meie 
patsientidelt isoleeritud bakteritüvedel. Antud tulemused võivad osutuda
58
tähtsaks erinevate etniliste gruppide puhul uute PPH ravi- ja  profülaktiliste 
strateegiate väljatöötamisel.
6. Erinevate maohaigustega Lõuna-Eesti patsientidelt isoleeritud H. pylori 
tüvedele on iseloomulik kõrge (87%) cagA geeni esinemissagedus. H. py­
lori tüvede jaotumus virulentsusmarkerite, cagA ja  vacA genotüübi, põhjal 
ei erinenud statistiliselt kroonilise gastriidi, mittetüsistunud haavandtõve 
ega PPH puhul.
7. Kõik käesolevas töös H. pylori eradikatsiooniks kasutatud raviskeemid 
osutusid PPH puhul ebaefektiivseks, mis seab kahtluse alla niisugusel kujul 
ravitaktika kasutamise Eesti patsientidel. Täpsem ebaedu põhjuste selgi­
tamine ning Eesti oludele sobiva ravitaktika väljatöötamine nõuab jätku­
vaid uuringuid.
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Summary
Introduction: The aim of this study was to assess the characteristics 
of perforated peptic ulcer (PPU) in Tartu county, Estonia, in 1981-2000.
Materials and Methods: All 426 patients with PPU from this de­
fined area, admitted during 1981-2000, were analysed in a retrospective 
study.
Results: Comparison of the periods 1981-90 and 1991-2000 revealed 
a sharp increase in PPU incidence from mean 7.4 to 20.0 per 100,000/ 
year (pcO.OOl). The annual incidences of PPU were significantly corre­
lated with the annual suicide rates for 1981-2000. PPU patients’ mean 
age and sex distribution did not change. The mean age was 46.7 years, 
being 62.2 years for females and 42.3 years for males (pcO.OOl). O f the 
patients 22.3% (95/426) were female and 30.4% (112/369) had a history 
of ulcer disease before perforation. PPU mortality remained fairly stable, 
6.0% (7/117) and 5.8% (18/309) in 1981-90 and 1991-2000, respectively 
(p=ns).
Conclusions: A pronounced increase in PPU incidence occurred in 
Tartu county without significant changes in patients’ mean age, sex dis­
tribution and outcome. The annual PPU and suicide rates were correlated.
Introduction
In recent decades the epidemiology of perforated peptic ulcer (PPU) 
has undergone considerable changes in the Western countries. PPU inci-
©2002 by Monduzzi Editore S.pA -  MEDIMOND Inc. C603C0402 199
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dence has decreased in young patients and males, but increased in elderly 
patients and females (1). Mean age of patients at the time of perforation 
has risen by 10-20 years (2, 3).
According to the reports of the Ministry of Social Affairs of Estonia 
increase in the incidence of PPU in Estonia has been considerable since
1991. The aim of this study was to examine the characteristics of PPU 
in a defined area in the southern part of Estonia, Tartu county, in the 20- 
year period from 1981 to 2000.
PPU has been associated with social stress (4), and suicide rate has 
been pointed out as an indirect stress parameter (5). Since not only PPU 
incidence, but also suicide rate was increasing rapidly in Estonia from 
1991 (6), we aimed to evaluate whether the PPU and suicide rates were 
statistically correlated for 1981-2000.
Materials and Methods
All 426 patients with PPU from the catchment area of Tartu county 
between 1981 and 2000 were included in a retrospective study. The es­
timated mean population of Tartu county was 156,993 (standard error 
±896) throughout the 20-year study period according to data published by 
the Statistical Office of Estonia. No considerable changes have taken 
place in the age or sex distribution of the population in this period.
Primary data for identification of patients were obtained from the 
computerised database of the hospital according to the discharge diagno­
sis. Further, case histories and logbooks of the operating theatre were 
studied. No changes took place in disease classification during the stud­
ied period.
The diagnosis of PPU was confirmed in 426 patients - in 398 patients 
on operation, in 4 patients on autopsy and 4 conservatively managed 
patients (with typical clinical signs, pneumoperitoneum on X-ray and 
endoscopically verified ulcer disease) were also included. Ulcers were 
classified into gastric (GU) and duodenal ulcers (DU), while DU com­
prised prepyloric (within 0.5-2.0 cm from the pyloric ring), pyloric and 
bulbar ulcers as described by Horowitz (7).
To compare the study periods, the patients were divided into two 
groups according to decades: period I (1981-90) and period П (1991- 
2000). The correlation between the annual incidences of PPU in Tartu 
county and the suicide rates in Estonia for 1981-2000 was evaluated 
using the Pearson correlation test. The data of the suicide rates in Estonia 
were drawn from the database of the Swedish-Estonian Institute of Sui- 
cidology. Mean values are presented as the mean ± standard error of the 
mean and were compared with the use of Student’s t-Test. Absolute 
figures were compared by using chi-square test with continuity correc­
tion. Differences were considered statistically significant for p values less 
than 0.05.
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Results
The incidence of PPU remained between 4 and 12 (mean 7.4±0.9) per 
100,000 per year in period I (Figure 1). In period П there occurred a 
sharp increase in incidence up to 26, which did not drop below 14 (mean 
20.0±1.3) (pcO.OOl). The Pearson correlation test revealed a statistically 
significant correlation between the annual incidences of PPU and the 
suicide rates in the period 1981-2000 (r=0.633, p=0.0027) (Figure 1).
An increasing tendency of PPU incidence was similar for both of male 
and female patients while the female:male ratio (1:4.1 in period I and 
1:3.3 in period II) did not reveal any significant changes (p=ns). Mean 
age was almost the same, 47.4±1.7 years in 1981-90 and 46.4±1.1 years 
in 1991-2000 (p=ns). The mean age of women, 62.2±2.0 years, exceeded 
significantly that of men 42.3±0.9 (pcO.OOl). Mean age for GU perfora­
tions was 56.9±2.3 years and for DU perforations 45.0±1.0 years (pcO.OOl).
GU perforations accounted for 11.1% (13/113) and 11.9% (37/304) of 
all perforations in periods I and П, respectively (p=ns). Of the patients 
30.4% (112/369) had a history of confirmed ulcer disease before perfo­
ration and 23.4% (94/402) had concomitant diseases.
Twenty-five patients (5.9%) of 426 with PPU died during 1981-2000. 
Mortality remained almost the same, 6.0% (7/117) in period I and 5.8%
Fig. 1. Incidences per 100,000 per year and the polynomial curves (calculated from 
the formula y=b+cfx+c2x2+cJx*) of perforated peptic ulcer (PPU) in Tartu county 
and of suicide in Estonia; number of PPU (females, males, total) in Tartu county in 
1981-2000.
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(18/309) in period II (p=ns). Mortality for females was 15.8% versus 
3.0% for males (pcO.OOl). However, it revealed no significant difference 
when different age groups were compared: 24.2% (8/33) for males and 
27.1% (13/48) for females, both aged >65, and 0.7% (2/298) for males 
and 4.3% (2/47) for females, both aged c65. The mean age of patients 
who died, 74.2±2.5 years, exceeded significantly that of patients who 
survived, 45.0±0.9 years (pcO.OOl).
Discussion
A sharp, 2.7-fold increase in PPU incidence was noted in Tartu in 
1991-2000 compared with 1981-1990, while the same pattern is charac­
teristic of the whole of Estonia. The PPU incidence of 20.0 for 1991-
2000 is at least 2-3 times as high as that reported from the Western 
countries, 2.3-9.2 (3, 8). There were no considerable changes in our 
patients’ mean age and sex distribution throughout the 20 years studied. 
However, the mean age of our patients was considerably lower (46.7 
years vs 53-63 years) and the proportion of female patients (22.3% versus 
about 40-60%) lower compared with the figures given in most Western 
studies (2, 3, 8, 9).
W e consider that factors as social stress, low anti-ulcer drug usage and 
possibly factors as smoking habits and high H. p y lo r i infection rates in 
our community could have a certain impact on such a sharp increase of 
PPU incidence.
Stress has been associated with the rise of PPU incidence (4, 10). Lam 
et al. (4) found a relationship between increase in PPU and society stress 
when Hong Kong underwent significant socio-economic and political 
changes in 1962-85. In 1991 independence was re-established in Estonia, 
which led to profound socio-economic changes: a drastic decline in economy 
and a fast increase in unemployment. Unemployment rate increased rap­
idly from 0.6% in 1990 to 10.0% in 1996 (11). The indirect parameters 
o f social stress, e.g. suicide rate (5), showed a similar trend - after a 
decrease in 1987-1990 (incidence 24.5-27.1) suicide rate has risen rap­
idly in Estonia since 1991 to attain the highest figures of the century 
(incidence 41.0 in 1994) (6). This hypothesis is strongly supported also 
by the occurrence of a positive correlation between our PPU incidence 
and suicide rate for 1981-2000.
Another point for discussion is use of anti-peptic-ulcer drugs. H2 blockers 
and proton pump inhibitors were introduced later in our community than 
in most developed European countries. Use of modem anti-ulcer drugs in 
Estonia per capita was several times lower than in Stockholm county, 
Sweden, whereas the number of operations for ulcer disease per capita in 
Estonia was almost 20 times higher in 1993-95 (12). Smoking plays an 
important role in ulcer perforation, especially in younger patients (13). 
Although respective data were not available for our studied patients, in
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our ongoing prospective study over 80% of PPU patients from the same 
area were daily smokers in 1997-2000 (unpublished data). At the same 
time, the proportion of daily smokers in general population was only 29- 
36% in the period 1990-2000 (14).
The role of the important aetiological factor of peptic ulcer, H. p y lo r i , 
has remained controversial in PPU (15, 16). The prevalence of H. p y lo r i  
infection in Estonia is higher than in the Western countries, affecting 78- 
87% of population in Southern Estonia (17). In a prospective study genotyping
H .pylori strains, the bacteria were detected in 98% of the PPU patients 
from the same area studied in 1997-99 (18).
Mortality of PPU patients in our study (mean 5.9% for 20 years) was 
considerably lower than in most recent studies (3, 9). Also, mortality 
rates did not change during the study period, differently from increasing 
trends established in Western studies (2, 9). The lower mortality can be 
related mainly to the younger structure of our PPU patient sample which 
did not reveal any increasing age trend.
In conclusion, a significant increase in PPU incidence occurred in 
Tartu county since 1991, while the annual incidences of PPU were sta­
tistically correlated with the suicide rates for the period 1981-2000. At 
the same time, the mean age and sex distribution of PPU patients as well 
as outcome did not reveal any change.
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ABSTRACT
Background/Aims: The aim of our study was to 
evaluate complications and possible risk factors for 
mortality in perforated peptic ulcer patients with a 
special reference to the fact whether definitive or 
non-definitive operation was performed. 
M ethodology. AH 394 patients (mean age: 45.5 
years; range: 15-93) from Tartu county hospitalized 
for PPU at Tartu University Clinic in the period 
1978-97 were included in a retrospective study. 
Remit«: Twenty-two patients (5.6%) of 394 died. In 
73 patients 93 concomitant diseases (mortality 
19,2%) and in 81 patients 114 complications were 
obeervod. There were 245 non-definitive operations 
and 141 definitive operations with a mortality rate of
7.3% and 1.4%, respectively. Univariate logistic 
regression analysis of 386 operatively treated 
patients revealed that age Ž65 years, concomitant 
diseasee, treatment delay >12 hours, female sex and 
non-definitive operations were significantly associat­
ed with mortality. However, multivariate analysis 
showed that only age >66 years and concomitant dis­
eases were independent predictors of mortality. 
Conclusion*: Patients’ high age and presence of 
concomitant diseases were related to lethal outcome 
after surgical procedure performed for perforated 
peptic ulcer. The result did not depend on die fact 
whether definitive or non-definitive operation was 
applied.
KEYWORDS.
Perforated peptic 
ulcer Surgery; 
Mortality risk 
factors
ABBREVIATIONS:
Perforated Peptic 
Ulcer (PPU); Non- 
Steroidal Anti- 
Inflammatory 
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val (Cl)
INTRODUCTION
There has been substantial decline in elective opera­
tions for peptic ulcer disease during recent decades fol­
lowing the introduction of H2-receptor antagonists (1). 
However, surgery for peptic ulcer complications, includ­
ing perforations, has not decreased despite the use of 
new powerful drugs (1-3). Moreover, with increasing age 
and concomitant diseases in perforated peptic ulcer 
(PPU) patients (4-6), high complication and mortality 
rates have remained a challenging problem for the sur­
geon. Several studies discussing safety and risk factors of 
definitive surgery in emergency situation have estab­
lished that definitive surgery in emergency situation is 
as safe as non-definitive (6-8), even in high risk patients 
(9,10). With a new understanding of peptic ulcer patho­
genesis and advent of new powerful medicines, simple 
operations as ulcer suturation, including laparoscopic 
management, are increasingly advocated for optimal 
surgical treatment in recent years (11-14). However, 
there can be indications for definitive surgery as well, at 
least in a select group of patients (8). The aim of our 
study was to evaluate complications, outcome and possi­
ble risk factors for mortality in PPU patients with a spe­
cial reference to the type of operation performed.
METHODOLOGY
All patients hospitalized for PPU at the Tartu Uni­
versity Clinic from Tartu county between 1 January 
1978 and 31 December 1997 were included in a retro­
spective study. Case reports or, in case of missing data, 
operation theatre logbooks of these 394 patients (mean 
age: 45.5 years; range: 15-93, 17.3% of patients >65
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years) were reviewed. The following data were recorded 
and entered into the database: patients’ age and sex, 
previous ulcer history, concomitant diseasee, shock on 
admission (systolic blood pressure < 100mm Hg), treat 
ment delay, ulcer location, operation, complications and 
outcome. There were 313 males and 73 females; accord­
ing to ulcer location, the perforations were classified as 
follows: 44 gastric and 337 duodenal (including prepy­
loric, Le., within 0.5-2.0cm of the pyloric ring, pyloric and 
bulbar) ulcers. Mortality was assessed during the tim p 
that the patient remained in hospital irrespective of the 
30-day period. We considered it impossible to evaluate 
data on non-steroidal anti-inflammatory drugB (NSAID) 
usage and smoking on the basis of these documents.
During the 20-year study period, a significantly 
increasing trend of PPU incidence was noted, while the 
proportion of definitive operations increased substan­
tially as well (unpublished data).
Evaluation of possible risk factors for mortality was 
carried out on 386 out of 394 (Le., only surgically treat­
ed) patients using univariate analysis. The analysis 
involving age, sex and operative method was performed 
on all patients; the other parameters (treatment delay, 
location of ulcer, general/local peritonitis, concomitant 
diseases, shock on admission, previous ulcer history) 
were evaluated using the data that were available. Non- 
operatively treated patients were exchided from risk 
stratification. Further multivariate logistic regression 
was performed to analyze mortality risk factors. Only 
significant factors (five) from univariate analysis were 
inchided in the modeL For other statistical analyses %2 
method was used. Statistical calculations were made
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T A B L E  1 Distributio n of 1 1 4  Com plications in 81 P P U  
Patie nts
No.of complications/ 
Complication deaths
Wound infection 26/2
Intraabdominal complications: 1 8 / 7
Dehiscence, abscess 6/3
Anastomoeitis 5/3
Bleeding 4 / -
Pylorostenosis 2/1
Reperforation V -
General complications: 7 0 /2 2
Cardiac insufficiency/failure 19/3
Pneum onia 11/2
Respiratory failure, pu lm onary embolism 5/3
Psychosis 7/1
M ultiple O rgan Failure 7/7
R enal failure 3/1
Sepsis 7/6
O thers 1 1 /-
T A B L E  2 D istributio n of 93 Con co m ita nt Diseases 
in 7 3  P P U  Patie nts
Patients aged 
<66year8 
n=320
Patients aged 
265years 
n=66
No of p atien ts 4 0 33
Diseases:
Cardiac insufficiency 6 23
P ulm onary 7 4
Tuberculosis in  anam nesis 6 2
Rheum atic 4 7
Gynecological 5
M alignancy 2 2
M ental disorders 4
Diabetes m ellitus 2 2
Hepatic 3 1
Neurological 4
O thers 7 2
T otal 50 43
T A B L E  3 Op e ra lio ns and O utc o m e  in 386 P P U  Patients
All patients Gastric ulcer Duodenal ulcer
(No. o f deaths) (No. o f  deaths) (No. o f deaths)
Non-definitive operations
Ulcer su tu ra tio n 183* (15) 35(3 ) 143 (12)
U lcer excision ± P P 62(3) 0 62(3)
Total 245* (18) 35 (3) 205 (15)
Definitive operations
TV + ulcer ex d s io n + P P 104 0 104
SPV + ulcer excision±PP 9 0 9
SPV+ su tu ra tio n 1 0 1
A ntrum ectom y BI, BII 24 (2 ) 9 (1 ) 15 (1)
TV + an trum ectom y BI 3 0 3
Total 141 (2) 9 (1 ) 132 (1)
* in  5 pa tien ts  th e  exact location of u lcer was unknow n
PP: pyloroplasty; TV: tru n ca l vagotomy; SPV: selective proximal
vagotomy; BI and  ВП: B illroth I  an d  П  resection
with Stata statistical software.
RESULTS
Of the 394 patients 22 died yielding an overall mor­
tality rate of 5.6%. In two patients perforation was diag­
nosed only on postmortem autopsy, and 20 patients who 
died had been operated. The mean age of the patients 
who died (71.8 years) exceeded significantly that of the 
patients who survived (43.9 years) (P=0.0001). Mortali­
ty of female patients (14.7%) exceeded significantly that 
of males (3.4%) (P=0.0004), however, the mean age of 
all women, 59.4 years, was significantly higher than that 
of men, 42.2 years (P=0.0001).
A total of 114 complications were observed in 81 
patients: 54 patients had one complication, 22 patients 
had two, 4 patients had three and 1 patient had four 
complications. There were 26 wound infections, 18 
intraabdominal and 70 general complications (Table 1). 
The commonest complications in the patients who died 
were multiple organ failure (7 patients) and sepsis (5 
patients).
Seventy-three patients had 93 concomitant medical 
illnesses on admission. The most frequent concomitant 
diseases were cardiac (29), pulmonary (11) and 
rheumatic (11) illnesses (Table 2). In 40 patients aged 
<65 years, 50 concomitant diseases (mortality 5.0%, 2 of 
40) and in 33 patients aged >65 years, 43 concomitant 
diseases (mortality 36.4%, 12 of 33) were recorded. Mor­
tality of patients with concomitant diseases, 19.2% (14 of 
73), exceeded significantly that of patients without 
them, 0.4% (1 of 277) (P<0.0001).
The operations performed on 386 patients are given 
in Table 3. In 245 patients non-definitive and in 141 
patients definitive operations were used with a mortali­
ty rate of 7.3% (18/245) and 1.4% (2/141), respectively. 
Fifteen deaths occurred in patients treated with ulcer 
suturation, three deaths occurred in the ulcer excision 
and pyloroplasty group and only two deaths were regis­
tered in patients treated with definitive operation (par­
tial gastrectomy). Table 4 presents comparison of two 
patient groups where different operation methods were 
employed. In the group of non-definitive operations, 
patients were significantly older, had longer treatment 
delay, higher percentage of concomitant diseases and 
higher proportion of gastric ulcers. Six patients had 
intraoperative complications: there were 3 splenic, 2 
bowel and 2 bile duct injuries.
The results of the evaluation of risk factors for mor­
tality by univariate logistic analysis are given in Table
5. Age >65 years, female sex, treatment delay >12 hours, 
concomitant diseases and non-definitive operation 
increased mortality risk on the basis of univariate anal­
ysis. Inclusion of all these five variables in a multivariate 
regression model revealed that only patients’ age >65 
years (OR 13.9, Cl 2.83-68.2, P=0.01) and concomitant 
diseases (OR 10.7, Cl 2.69-42.4, P=0.01) were signifi­
cant (independent) predictors of mortality.
DISCUSSION
Optimal management of patients with PPU is still a 
matter of discussion. After a significant decrease in elec­
tive ulcer surgery since the 1970s (1,15), the number of 
operations for peptic ulcer disease complications has 
remained almost stable (1-3,16,17). Decrease in mortali­
ty rates, from 20-30% in the 1930s-1940s (18) to about 5- 
10% in the 1970s (5,7,19), has not been observed in the
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T A B L E  4 Patie nt Ch aracteristics Acco rd ing  to O p eration T yp e
Factor Non-definitive op. Definitive op. X2 test, 
P  value
No. of p a tien ts 245 141
M ean age (years) 47.2 42.5 P < 0 .05
M ale:female ratio 196:49 117:24 NS
Previous u lcer h istory 54 (27.4%) 46 (38%) NS
T reatm en t delay <12 hours /  £12 hours 163:68 (70.6%:29.4%) 119:16 (88.2%:11.8%) P <  0.001
Concom itant disease 54 (24.7%) 18 (14.1%) P< 0 .05
Gastric/duodenal ulcer 35:205 (14.6%:85.4%) 9:132 (6.4%:93.6%) P< 0 .05
Perforation  size <6m m / >6mm 164:49 (77%:23%) 99:31 (76.2%:23.8%) NS
T A B L E  5 Results ot E va lu a tio n  of Possible R isk Fac to rs  for M o rtality on Univariate  logistic Regression Analysis
Factor No. o f Mortality 
patients N (%) O R C l  9 5 % P  value
Age <65: >65 years 320:66 3:17 (0.9%:25.8%) 36.7 10.4-129.7 P<0.001
Male: female 313:73 10:10 (3.2%:13.7%) 4.8 1.9-12.0 P < 0.01
T reatm en t delay <12:512 hours 
Non-definitive: definitive operation
303:81 8:12 (2.6%:14.8%) 
245:141 18:2 (7.3%:1.4%)
6.4
5.5
2.5-16.2
1.3-24.1
P<0.001 
P <  0.05
D uodenahgastric u lcer 337:44 16:4 (4.7%:9.1%) 2.0 0.6-6.3 NS
G eneral:localized peritonitis* 333:42 20:0 (6.0%:0%) 2.7 0.4-16.0 NS
Concom itant disease yes:no 72:277 13:2 (18.1%:0.7%) 30.3 6.7-137.8 P<0.001
Shock yes:no 17:320 1:14 (5.9%:4.4%) 1.4 0.2-11.0 NS
Ulcer h istory  yes:no 101:255 2:15 (2.0%:6.0%) 0.3 0.7-1.3 NS
* to  calculate OR, value 0 was sub stitu ted  for by value 1. 
OR: odds ratio; Cl: confidence in terval
1980s-1990s (5,20). Moreover, mortality figures as high 
as 17-31% can be found in literature (4,9,21,22). Ibis 
trend can be explained mainly by changes in the struc­
ture of PPU patient population. During recent decades 
patients’ mean age has increased by about 20 years 
(5,23,24); the proportion of female patients makes up 
nearly one half or even exceeds it (4-6,8,21); older 
patients have concomitant diseases more often (6,21) 
and use NSAIDs more frequently (8,23,25). Svanes et al 
found that increasing mean age of patients may conceal 
better results in the management of PPU patients, and 
hence mortality figures do not increase when adjusting 
to age groups (26). In our study the mean age of patients 
(45.5 years) and the proportion of female patients 
(17.4%) were considerably lower, and overall mortality 
(5.6%) was also lower compared with the above studies. 
We believe that such low mortality rate in our series can 
be largely explained by the low mean age of patients.
There has been much discussion about the choice of 
surgical procedure in case of emergency operation. In 
our study 245 non-definitive operations with a mortality 
of 7.3% and 141 definitive operations with a mortality of 
1.4% were performed. However, comparison of the 
patients of the two groups (Table 4) revealed that high­
er mortality rates for non-definitive operations resulted 
from the effect of the surgeon’s decision on the choice of 
operation. Patients with probable risk factors served as 
more eligible candidates for non-definitive procedure, 
since it was thought to be safer. Our results of multifac­
torial analysis revealed that operative method had no 
independent effect on mortality. Numerous data give 
evidence of better long-term results after definitive oper­
ation: recurrence rate is lower and the patient’s self-esti­
mation of his/her condition is higher (27-29). Several
studies have confirmed that there is no reason to fear for 
higher mortality in emergency situation when definitive 
procedures are applied (6,9,30,31); in this respect non­
definitive operations appear to have no advantages even 
in high risk patients (10,32,33). Our results demonstrate 
agreement with the above investigations. However, 
definitive surgery for PPU has shown fast decline, which 
is mainly supported by new ideas as well as the knowl­
edge of the pathogenesis of ulcer disease and of the role 
of Helicobacter pylori in it (12-14). At the same time, the 
importance of H. pylori infection itself in perforated pep­
tic ulcer is not clear. In contrast with opinions in favor of 
the crucial role of H. pylori (34-38) several researches 
have opposed to this idea (39-42), maintaining that. PPU 
represents even a specific subgroup of peptic ulcer dis­
ease (43).
Different studies have described about ten risk fac­
tors predicting outcome and morbidity in PPU patients, 
the most frequent being old age, concomitant diseases, 
treatment delay and shock on admission (7- 
9,19,22,31,44), but also gastric ulcer location (9,20,26), 
hospitalization {it the time of perforation (9), large diam­
eter of perforation (45), use of steroids (9), leukocyte rate 
less than 9.500/mm3 (44) and reperforation (8). Univari­
ate analysis of our data revealed that high age (>65 
years), concomitant diseases, treatment delay >12 hours, 
female sex and non-definitive operation are risk factors 
for mortality, whereas location of ulcer, shock on admis­
sion and previous ulcer history had no influence on mor­
tality. However, only high age and concomitant diseases 
remained significant in multivariate analysis. Apart 
from non-definitive surgery discussed above, neither 
treatment delay or female sex had independent effect on 
mortality in multifactorial analysis. The influence of the
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female sex on outcome appeared to be a biased effect as 
well, as the mean age of women was significantly higher 
tJmn that of males.
Wakayama et al concluded that old age alone con­
tributed to lethal outcome (44), while others found that 
old age alone (without concurrent factors) did not pre­
dict outcome (7,8). Our results are in accord with the 
studies where old age per se was found to predict out­
come.
In conclusion, patients’ high age and presence of 
concomitant diseases predicted outcome after surgical 
procedure performed for PPU. The result did not 
depend on the fact whether definitive or non-definitive 
operations were applied.
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Abstract Background and aims: 
Ulcer surgery and the epidemiology 
of peptic ulcer perforation have 
changed considerably in recent de­
cades. Patients/methods: Within two 
prospective studies, 170 perforated 
peptic ulcer patients from 12 Eastern 
European centres and 37 patients 
from 11 German centres were analy­
sed. Results: The median age of pa­
tients was 43 years in the Copernicus 
study and 49 years in the MEDWIS 
study (P=n.s.), being higher for 
MEDWIS female patients (73 vs 
53 years, respectively; Л<0.05). Fe­
male patients made up 17% (29/170) 
of the Copernicus study and 35% 
(40/170) of the MEDWIS study 
(P<0.05). Twenty-three per cent 
(40/170) of patients in the Coperni­
cus study and 54% (20/37) in the 
MEDWIS study had gastric ulcer 
perforation (PcO.OOl). The propor­
tion of definitive operations was 
higher in Eastern Europe (41.1%;
67/163) than it was in Germany 
(16.1%; 5/31) (/><0.01). German pa­
tients experienced more general 
complications than Eastern European 
patients (35 vs 12%, respectively; 
PcO.Ol) and a higher mortality [13% 
(5/37) vs 2% (4/170), respectively; 
PcO.Ol]. Delayed admission >12 h 
and age >60 years remained predic­
tors for complications in multivariate 
logistic regression analysis. 
Conclusion: The proportion of both 
women and gastric ulcers was higher 
among German patients, while East­
ern European patients underwent 
more definitive operations. German 
patients experienced more general 
complications and a higher mortality. 
Complications were related to high 
age and delayed admission.
Key words Perforated peptic ulcer • 
Operative treatment ■ Complications • 
Risk factors
Introduction
Substantial changes in the conservative therapy of ulcer 
disease have significantly reduced elective peptic ulcer 
surgery since the 1980s. However, no decrease has been 
noted in emergency ulcer surgery [1, 2,3], including that 
for perforated peptic ulcer (PPU). The epidemiology of 
PPU in developed countries has changed considerably in 
recent decades. Median age at the time of perforation has 
increased by 10-20 years (about 60-70 years in the 
1990s) [4,5]. Being previously a disease predominantly
affecting men [male:female (M:F) ratio about 10:1], PPU 
is now increasingly affecting elderly women (M:F ratio 
1.5:1) [2, 3,4]. The use of non-steroidal anti-inflammato­
ry drugs (NSAIDs) among PPU patients has increased 
[6,7]. The rate of complications and mortality have not 
declined during recent decades. Mortality is reported to 
vary between 5 and 31% [2, 4, 5, 7, 8, 9,10]. Higher age, 
delayed treatment, concomitant diseases, presence of 
shock on admission and location of the ulcer in the gas­
tric corpus have been cited as the main risk factors for 
complications and mortality [7, 9, 11, 12, 13,14]. During
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recent decades, non-definitive operative methods, mainly 
ulcer suturation (also performed by laparoscopic meth­
ods), are increasingly being advocated for optimal surgi­
cal treatment of PPU [6, 15, 16, 17,18]. The aim of our 
study was to compare PPU patients’ characteristics, 
treatment policies, complications and the outcome of an 
Eastern European multicentre study (Copernicus) with 
the respective data of a German study (MEDWIS).
Patients and methods
Sixteen centres from nine countries participated in an Eastern Eu­
ropean prospective multinational study of acute abdominal pain 
(Copernicus European Concerted Action 555) [19]. Ten centres 
from Germany and one from Austria participated in a similar 
study of acute abdominal pain (MEDWIS A 70) [20]). In both 
studies, all patients who experienced acute abdominal pain within 
1 week before hospital admission were included. A structured, 
standardised medical history was drawn up for all patients and a 
physical examination was performed according to international 
standards. These clinical findings together with the data of labora­
tory investigations, ultrasound, X-ray, diagnosis, operative proce­
dure and outcome were documented prospectively using a com­
puter program. A software package with multilingual program 
versions was developed for documentation. The same standardised 
definitions were used for all parameters in both studies. Data col­
lected at the centres were transmitted anonymously to the central 
study secretariat in Düsseldorf and were examined with respect to 
completeness and quality. Physicians participating in the study 
were contacted in cases of missing or unclear data. Patient recruit­
ment took place between 1 January and 31 October 1997 for the 
Copernicus study; 4020 patients from 12 centres were included, 
among whom 170 (4.2%) had a final diagnosis of PPU. The MED­
WIS study, which included a total of 2280 patients, of whom a fi­
nal diagnosis of PPU was confirmed in 37 (1.6%), was conducted 
between October 1994 and March 1996. All patients with a final
diagnosis of PPU were analysed in this particular report Data for 
PPU patients’ characteristics, performed operations, outcome and 
mortality were compared for the two studies. Ulcerogenic drugs 
included NSAIDs and glycocorticoids. Non-definitive operations 
included ulcer excision or suturation, while definitive operations 
included vagotomy and gastric resection. The risk factors for com­
plications in PPU patients were evaluated by pooling the data of 
the two studies. In the comparison of characteristics for each vari­
able, patients with missing data were excluded. Medians with per­
centiles of 25-75 were calculated for age. Absolute numbers were 
compared by means of the chi-square test with continuity correc­
tion. The Mann-Whitney test was used for continuous variables. 
Multivariate analysis with stepwise logistic regression (BMDP 
LR) involved variables that proved to be significant in univariate 
analysis using the default values of the program (enter limit: 0 .1, 
remove limit: 0.15).
Results
Among the 170 Copernicus patients with PPU, male pa­
tients outnumbered females (M:F) by a ratio of 141:29. 
Among the 37 MEDWIS patients with PPU, the M:F ra­
tio was only 24:13 (Table 1) (P<0.05). Median age was
43.0 (33.0-55.3) years for the Copernicus patients and
49.0 (32.0-73.0) years for the MEDWIS patients 
(P=n.s.). However, for female patients, it was 53.0 
(40.5-71.5) years in the Copernicus study and 73.0 
(55.0-82.0) years in the MEDWIS study (Р<0.05). There 
was a significant difference in ulcer location between the 
studies, gastric ulcer perforations accounting for 23.5% 
(40/170) in the Copernicus study and 54.1% (20/37) in 
the MEDWIS study ( / ’<0.001). Comparison of the two 
studies revealed no significant differences in terms of de­
lay on admission, shock on admission, previous dyspep-
Table 1 Characteristics of patients with perforated peptic ulcer in the Copernicus (n=170) and MEDWIS (n= 37) studies, n.s. not signifi­
cant
Variable Copernicus MEDWIS P value
n % n %
Sex Male 141 82.9 24 64.9 <0.05
Female 29 17.1 13 35.1
Ulcer location Duodenal 130 76.5 17 46.9 <0.001
Gastric 40 23.5 20 54.1
Delay on admission» (h) <12 125 75.8 24 64.9
12-24 26 15.8 8 21.6 n.s.
>24—48 5 3.0 0 0.0
>48 9 5.5 5 13.5
Shock on admission* Yes 20 12.3 9 24.3 n.s.
No 143 87.7 28 75.7
Previous dyspepsia1 Yes 97 60.6 20 58.8 n.s.
No 63 39.4 14 41.2
Previously diagnosed ulcer2 Yes 63 41.7 11 34.4 n.s.
No 88 58.3 21 65.6
Ulcerogenic drugs* Yes 13 8.1 6 18.8 n.s.
No 148 91.9 26 81.3
1 Patients with missing data excluded
346
Table 2 Distribution of opera­
tions in patients with perforated 
peptic ulcer (PPU) (patients 
with missing data excluded)
a Truncal vagotomy. 
b Selective proximal vagotomy.
Table 3 Complications in 31 
Copernicus patients and 10 
MEDWIS patients with perfo­
rated peptic ulcer (PPU). 
rus. not significant
1 One patient with missing data 
excluded.
Table 4 Results of evaluation 
of risk factors for complica­
tions in perforated peptic ulcer 
(PPU) patients in univariate 
analysis
* Patients with missing data ex­
cluded.
Copernicus 
n %
MEDWIS
n %
P value
Nondefinitive operations 96 58.9 26 83.9
Oversewing of ulcer 65 10
Ulcer excision 29 16
Laparoscopic management 2 0
Definitive operations 67 41.1 5 16.1 <0.01
Billroth I resection 6 3
Billroth II resection 6 2
TV Ч-ulcer excision 51
SPVb+ulcer excision 3
SPW ulcer suturation 1
Total 163 100 31 100 -
Complication Copernicus* (A t 169 N) MEDWIS (ЛЬ37) P value
n % n %
Intraabdominal 11 6.5 2 5.4 n.s
(peritonitis/abscessus)
Wound infection 9 5.3 2 5.4 n.s.
General complications 21 12.4 13 35.1 <0.01
Pneumonia 7 5
Pulmonary failure 3 2
Renal failure 1 1
Hepatic failure 1 -
Other 9 5
Total (overall) 31 18.3 10 27.0 n.s.
Variable Complication(s)
(N=41)
n %
No complications 
(N=165)
n %
P value
Sex Male 28 68.3 136 82.4 <0.05
Female 13 31.7 29 17.6
Age (years) <60 20 48.8 139 84.2 <0.001
£60 21 51.8 26 15.8
Ulcer location Duodenal 25 61.0 121 73.3 n.s.
Gastric 16 39.0 44 26.7
Operationa Definitive 11 27.5 61 39.9 n.s.
Non-definitive 29 72.5 92 60.1
Delay on admissiona (h) <12 21 53.8 127 78.4 <0.01
>12 18 46.2 35 21.6
Shock on admissiona Yes 6 15.8 23 14.3 n.s.
No 32 84.2 138 85.7
Previously diagnosed ulcera Yes 16 44.4 58 39.7 n.s.
No 20 55.6 88 60.3
Ulcerogenic drugsa Yes 5 13.2 14 9.1 n.s.
No 33 86.8 140 90.9
White blood cell counta <9000 15 42.9 53 34.6 n.s.
£9000 20 57.1 100 65.4
Study Copernicus 31 75.6 138 83.6 n.s.
MEDWIS 10 24.4 27 16.4
21
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Table 5 Results of multivariate 
analysis of risk factors for com­
plications in perforated peptic 
ulcer (PPU) patients
Variable P-value
ß
Coefficient Coefficient/SE
exp(ß)
Odds ratio
Age >60 years 0.001 1.512 3.83 4.54
Delay on admission >12 h 0.012 1.006 2.56 2.73
Constant - -2.220 -7.81 0.109
sia, previously diagnosed ulcer or ulcerogenic drug us­
age.
The distribution of operations performed on PPU patients is 
shown in Table 2. In the MEDWIS study only five (16.1%) pa­
tients were operated on using a definitive method, while in the Co­
pernicus study 67 (41.1%) patients underwent a definitive opera­
tion (P<0.01). At the same time, the proportion of definitive sur­
gery varied from 0 to 91% at different centres of the Copernicus 
study. In the MEDWIS study, no vagotomies were performed for 
PPU.
There were no significant differences in the overall 
complication rate; however, 35.1% (13/37) of MEDWIS 
patients experienced general complications compared 
with 12.4% (21/169) of Copernicus patients (/*<0.01) 
(Table 3).
A total of nine patients died during the course of the 
study: 2.4% (4/170) from the Copernicus study and 
13.5% (5/37) from the MEDWIS study (/><0.01). 
Among these nine patients, there were four males and 
five females with a median age of 80 (65-93) years, in 
whom four gastric and five duodenal ulcer perforations 
had been diagnosed.
Results of the comparison of 41 patients with compli­
cations and 165 patients without complications in uni­
variate analysis for risk factors for complications are 
given in Table 4. Three variables -  age Ž60 years 
(/*<0.001), delay on admission Ž12 h (/’<0.01) and fe­
male sex (P<0.05) -  proved to be significant predictors 
for complications. On the inclusion of these three vari­
ables in multivariate analysis with stepwise logistic re­
gression, only age >60 years and delay on admission 
>12 h remained significant predictors for complications 
in PPU patients (Table 5).
Discussion
Within two multicentre prospective studies, conducted at 
12 centres in Eastern Europe and 11 centres in Germany 
and Austria, data were collected according to standardi­
sed protocols, which allowed the comparison of research 
results. Of all studied patients with acute abdominal 
pain, 4.2% in Eastern Europe and 1.6% in Germany had 
a final diagnosis of PPU, which is comparable with the 
results of several previously reported series [21,22,23].
The main distinctive characteristics of PPU patients 
in the two studies were sex and ulcer localisation. 
Among German and Eastern European patients, the pro­
portion of females was 35.1 vs 17.1% and the proportion
of gastric ulcer perforations was 54.1 vs 23.5%, respec­
tively. In the German study, the proportion of females is 
closer to the figures reported for the Western countries in 
recent decades at 40-60% [2, 4, 8,10], while the respec­
tive proportion for Eastern Europe is clearly divergent. 
The higher proportion of gastric ulcers in the German 
study is in agreement with data indicating an increasing 
trend in Western patients [2,4].
Median age did not reveal any significant difference, 
being 43 years for Copernicus patients and 49 years for 
MEDWIS patients. Both figures are lower than the pre­
viously reported median age of 62-66 years [4,10]. 
However, the higher median age of German female pa­
tients compared with that of their Eastern European 
counterparts (73 vs 53 years) can be explained by the 
above-described trends in the Western countries.
The other variables, i.e. delay on admission, shock on 
admission and previously diagnosed ulcer disease, did 
not reveal differences between Eastern European and 
German patients. There were relatively few users of ul­
cerogenic drugs in either study (8.1 and 18.8%, respec­
tively) compared with the reported proportion of 
40-70% [5, 24, 25,26].
The distribution of different operations in the two 
studies was quite different, with definitive operations ac­
counting for 16.1% in the German study and 41.1% in 
the Eastern European study. At different Eastern Europe­
an hospitals, the proportion of definitive surgery varied 
in the range of 0-91%, while five centres only used non­
definitive operations. At the same time, in the German 
study, only gastric resections were used among the five 
definitive operations, whereas in the Eastern European 
study, besides 12 gastric resections, 55 operations com­
bined with vagotomy were also performed. The high 
proportion of definitive operations is a characteristic fea­
ture of Eastern Europe. By contrast, according to the da­
ta of recent reports, the number of definitive procedures 
is diminishing rapidly in the Western countries [10, 16, 
27, 28,29].
Overall complication rates -  18.3% in the Copernicus 
study and 27.0% in the MEDWIS study -  did not reveal 
significant differences; however, the proportion of pa­
tients with general complications was 12.4 and 35.1% 
(P<0.01), respectively. Like the other variables, the over­
all complication rate in German patients is closer to 
30-57% reported in most Western studies [12, 30,31], 
while the figure for Eastern European patients is compa­
rable with that reported by Boey et al. [32], i.e. 14%.
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Higher figures for general complications in German pa­
tients can be attributed to the different structure of the pa­
tient sample in either study. The higher proportion of fe­
males with higher median age may play some role in the 
development of general complications, as far as a trend of 
increase in general complications with the ageing of pa­
tients has been observed in the Western countries [4].
Differences in mortality -  13.5% for the MEDWIS pa­
tients and 2.4% for the Copernicus patients -  can also be 
explained by the different structure of the two patient 
samples. All patients who died were at least 65 years old.
The mortality rate of 13.5% in the MEDWIS study 
was comparable with the rate of 6-31% reported for the 
Western countries in the 1990s [5, 10, 12], while the rate 
of 2.4% for Copernicus patients was significantly lower.
In univariate analysis, age Ž60 years, delayed treatment 
Ž12 h and female sex were significant predictors in the de­
velopment of complications. In multivariate analysis, 
however, only high age and delayed treatment remained 
independent predictors for complications. These two fac­
tors have also been pointed out in a number of other stud­
ies [11, 14, 30, 31, 32,33]. Complications were not related 
to either ulcer location or to the applied operation method.
Conclusion
In the German study, the proportion of both women among 
PPU patients and gastric ulcer perforations were higher 
than that of the respective characteristics for Eastern Euro­
pean patients. In aiddition, German female patients had a 
higher median age. The number of general complications 
and the mortality rate were higher in the German study. 
Non-definitive operations prevailed in the treatment of 
PPU in German patients, while the percentage of definitive 
operations was significantly higher for their Eastern Euro­
pean counterparts. The main complication related risk fac­
tors -  delayed admission >12 h and age >60 years -  were 
comparable with the data of most reports.
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Abstract
To compare the genomic variation of Helicobacter pylori in samples obtained from patients with perforated peptic ulcer, living in the same 
area of Estonia but belonging to different nationalities, 50 non-consecutive patients (32 Estonians and 18 Russians) admitted in the Tartu 
University Hospital in 1997-1999 were studied. Gastric samples of antral mucosa were obtained during operation and analysed 
histologically and with PCR for detection of different genotypes of H. pylori (cagA and vacA s and m subtypes). Among the 50 perforated 
peptic ulcer patients with histologically proven H. pylori colonisation no sample of gastric mucosa showed the sib subtype of the vac A gene. 
The perforated peptic ulcer patients were mainly infected with cagA (82%) and si (98%) genotypes of H. pylori. The distribution of sla/ml, 
sla/m2 and s2/m2 subtypes of vac A genes was statistically different in Estonian and Russian patients (P < 0.05). In conclusion differences in 
the distribution of vacA s and m subtypes of H. pylori were revealed between Estonian and Russian patients with perforated peptic ulcer 
from Southern Estonia. © 2001 Federation of European Microbiological Societies. Published by Elsevier Science B.V. All rights 
reserved.
Keywords: PCR; Ethnic tropism; cagA; vac A; Helicobacter pylori
1. Introduction
Helicobacter pylori plays an important role in gastritis, 
peptic ulcer disease and gastric malignancy [1]. To date, 
several products of H. pylori genes (vacA and its subtypes, 
cagA, ice), acting as disease-associated pathogenic factors 
in infected persons, have been identified [2-4]. A key fea­
ture of H. pylori is the enormous genomic micro-diversity 
of its strains distributed over the globe, even many indi­
viduals appear to be infected by a unique strain.
At the same time, different countries seem to be char­
acterised by a particular geographic pattern of different 
H. pylori genotypes [5,6]. In Western populations, gastric 
atrophy, duodenal ulceration, intestinal metaplasia, gastric 
carcinoma are more common among patients infected with 
cagA positive than among patients infected with cagA
* Corresponding author. Tel.: +372 (7) 374-171; 
Fax: +372 (7) 374-172; E-mail: marikam@ut.ce
negative strains [4,5]. Yet, in China and Japan the associ­
ation between cagA positivity and virulence of H. pylori 
strains was equally frequent among both diseased and 
control patients [5,7]. Recently, it was shown that in 
East Asia and in the Western countries, distinct variants 
of H. pylori cagA genes were associated with particular 
vacA subtypes [8].
However, the clinical significance of the genetic markers 
of H. pylori has not yet definitely been proved. Particu­
larly, the incidence of peptic ulcer disease is not reflected 
in the frequency of different H. pylori lineages among 
Polynesians and European New Zealanders [9]. Obviously, 
further research is needed to compare differences in the
H. pylori genome between particular ethnic groups with 
the same underlying disease, living in the same geographic 
region.
In Estonia, an increase in perforated peptic ulcer (PPU) 
has been noted since 1991-1997, the mean incidence for 
Southern Estonia amounting to 21/100000 [10]. At the 
same time, in Western countries the incidence of PPU
0378-1097/01/$20.00 © 2001 Federation of European Microbiological Societies. Published by Elsevier Science B.V. All rights reserved. 
PH: S 0 3 7 8 - 1 0 9 7 ( 0 0 ) 0 0 5 4 0 - l
30 T. Sillakivi el ul. IFF.MS Microbiology Leiters 195 12001) 29-33
has been kept in the range less than 10/100000 in recent 
decades [11]. Estonia is a state in Eastern Europe, lying on 
the coast of the Gulf Finland, with a population of about
1.5 million and area of 45000 km2. The Estonian popula­
tion consists of two-thirds of native Estonians and one- 
third of other nationalities, mainly Russians. In the 
present study an attempt was made to compare the ge­
nomic variation of H. pylori in samples obtained from 
patients with PPU, living in the same area of Estonia 
but belonging to different nationalities.
2. Materials and methods
2.1. Patients
HC1 (pH 8.0), 25 mM EDTA, 300 mM NaCl, 1.2% so­
dium dodecyl sulfate) and stored at — 20°C. Different ge­
notypes (cagA and vac A s and m subtypes) of H. pylori 
were assessed. DNA was extracted from a frozen gastric 
biopsy specimen using the following procedure: 10 pi of 
the proteinase К (400 pg ml-1) was added to the biopsy 
specimen suspended in the lysis buffer (500 pi). The mix­
ture was incubated at 37°C for 24 h. The lysate was ex­
tracted with an equal volume of phenol-chloroform and 
precipitated with ethanol. A DNA pellet was collected by 
centrifugation, washed with 70% ethanol and finally resus­
pended in 35-50 |il of ТЕ buffer (10 mM Tris-HCI (pH 
8.0), 0.1 mM EDTA). For analysis of the s and m regions 
of vac A and for detection of the cagA gene, the primers 
shown in Table 1 were used.
The study was carried out at Tartu (Southern Estonia) 
University Hospital from January 1, 1997 to December 31, 
1999. During this period 129 patients with PPU were hos­
pitalised. Informed consent was obtained from all patients 
who were questioned using a standard questionnaire. Only 
the patients (и = 53) of whom both parents could be iden­
tified as being of the same nationality were included. All 
patients were operated and three gastric specimens of the 
antral mucosa were taken intra-operatively through the 
perforation, or postoperatively on pan-endoscopy. Two 
of the specimens were analysed by histological methods 
and one by molecular methods.
2.2. Histological evaluation
Biopsy specimens were fixed overnight in neutral buff­
ered formalin and embedded in paraffin. Tissue sections 
were stained by the modified Giemsa method for semi- 
quantitative assessment of H. pylori colonisation as de­
scribed earlier [12].
2.3. Molecular evaluation
For analysis with molecular methods the specimens 
were placed into 500 pi of lysis buffer (200 mM Tris-
2.4. PCR conditions and amplification
Reaction mixtures were prepared in a volume of 50 pi, 
containing 0.3 pM concentration of each primer; 0.2 mM 
concentration of deoxynucleoside triphosphates; 10X re­
action buffer (200 mM Tris-HCI (pH 8.5), 500 mM KC1, 
10 mM MgCl2, 0.01% (w/v) gelatin); 1 mg ml-1 albumin 
(BSA); 2.5 mM MgCl2; 5 U of Taq DNA polymerase 
(Fermentas); and ~  10 ng DNA sample. The mixtures 
were placed in a PCR thermocycler (Biometra, Eppen­
dorf). Thermal cycling for all primer pairs comprised
4 min of preincubation at 95°C, followed by one cycle 
of 1 min at 95°C, 1 min 10 s at 56“C, 30 s at 72°C; three 
cycles of 1 min at 95°C, 1 min 10 s at 54°C, 30 s at 72°C; 
36 cycles of 1 min 95°C, 1 min 10 s at 52°C, 30 s at 72°C. 
PCR products were identified by electrophoresis on 2% 
agarose gels.
2.5. Statistical analysis
The mean values of patients’ age were compared by 
employing the Student r-test. The absolute figures of prev­
alence were compared by using the Chi-square test with a 
continuity correction. Differences were considered statisti­
cally significant for P values less than 0.05.
Table 1
PCR primers for amplification of vacA sequences and cagA gene of H. pylori
Amplified region Primer destination Primer sequence Product size (bp) Source of reference
si VA1-F ATGGAAATACAACAAACACAC И
VA1-R CTGCTTGAATGCGCCAAAC 259
sla S S I-P GTCAGCATCACACC GCAAC 190
sib SS3-P AGCGCCATACCGCAAGAG 187
s2 SS2-P GCTAACACGCCAAATGATCC 199
ml VA3-F GGTCAAAATGCGGTCATGG
VA3-R CCATTGGTACCTGTAGAAAC 290
m2 VA4-F GGAGCCCCAGGAAACATTG
VA4-R CATAACTAGCGCCTTGCAC 352
cagA D008 ATAATGCTAAATTAGACAACTTGAGCGA [13,14]
R008 TTAGAATAATCAACAAACATCACGCCAT 297
"Used in combination with primer VA1-R.
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Fig. 1. cagA and vacA status of H. pylori in antral mucosa samples of Estonian and Russian patients with PPU (*vac<4 subtypes distribution difference 
/> = 0.037).
3. Results
H. pylori was detected histologically in the antral mu­
cosa of 52 out of 53 included PPU patients (98%). The 
degree of colonisation in the antral mucosa varied from 
grade 1 to grade 3 (grade 1: <20 microbes per field; 
grade 2: 20-60 microbes per field; grade 3: >  60 microbes 
per field).
Using a PCR technique H. pylori was detected in the 
antral mucosa of 51 PPU patients (96%). In one patient 
with no detected vac A or cagA genotype, H. pylori was 
still proven to be present histologically.
In one Estonian male, with a cagA positive sample, two 
vac A gene subtypes (si a/ml and sla/m2) were found si­
multaneously and the patient was excluded from further 
analysis when comparing H. pylori subtypes in persons of 
different nations. The distribution of the remaining 50 H. 
pylori positive samples from 32 Estonians and 18 Russians 
according to the markers of cagA and vacA gene subtypes
is presented in Table 2. Among H. pylori positive samples, 
41 (82%) were cagA positive. The most frequent was the 
si a/ml vac A subtype (32 cases), while the sib subtype was 
not found in our PPU patients.
Both si subtypes (s 1 a/m 1 and sla/m2) prevailed (98%) 
in cagA positive samples. Comparison of the distribution 
of the pattern of three vac A subtypes in patients with cagA 
positive and negative strains by using Chi-square test 
yielded statistical difference at the level P<  0.001 (Table 
2).
No differences were observed in the distribution of cagA 
positive or negative markers between Estonian and Rus­
sian patients with PPU, as the cagA gene was revealed in 
81% (26 of 32) and 83% (15 of 18) of cases, respectively 
(Fig. 1). In contrast, the distribution of vac A subtypes was 
different in the gastric samples of our Estonian and Rus­
sian patients. The si a/ml subtype was found in 75% (24 of 
32) of Estonians but in only 44% (8 of 18) of Russians. At 
the same time, the sla/m2 subtype was more frequent in
Table 2
Distribution of H pylori cagA and vacA status in PPU patients
vacA subtype cagA*, n = 41 cagA , л = 9 Chi-square
sla/ml 29 (71%) 3 (33%)
sla/m2 11 (27%) 1 (11%) /><0 001
s2/m2 1 (2%) 5 (56%)
Total 41 (100%) 9 (100%)
23
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Russians (44%, eight cases) than in Estonians (13%, four 
cases). The s2/m2 subtype was detected in four (13%) Es­
tonians and two (11%) Russians. Comparison of the dis­
tribution of three vacA subtypes in the gastric mucosa 
samples of PPU patients of different nationalities using 
Chi-square test yielded statistical difference (P = 0.037). 
No significant differences were revealed in the distribution 
of age, sex, smoking habits or ulcer location among our 
Estonian and Russian PPU patients.
4. Discussion
We investigated the distribution of H pylori genotypes 
in Southern Estonia among patients with complicated, his­
tologically proven H. pylori associated peptic ulcer disease. 
Using PCR method the genotypes of H. pylori were esti­
mated according to the presence of the cagA gene and 
vac A gene subtypes in specimens of gastric antral mucosa.
The fact that we did not find any gastric mucosa sample 
containing the sib  subtype of the vac A gene among the 50 
PPU patients investigated by us confirms the existence of 
geographical differences between H pylori genotypes. 
Also, although the sib  subtype was not found in H. pylori 
from Asian patients [15], it has been established in several 
studies conducted in Portugal, The Netherlands, and the 
USA [3,9,16]. However, as Estonia is situated in Eastern 
Europe, geographic differences between H. pylori geno­
types cannot be linked with different continents.
Furthermore, in our study the distribution of sla/ml, 
sla/m2 and s2/m2 subtypes of vac A genes was statistically 
different in Estonian and Russian patients (P <  0.05), both 
groups living in South Estonia. This confirms data about 
the ethnic tropism of H. pylori, suggested by Campbell et 
al. [9]. Yet these authors associated differences between the 
H. pylori strains colonising Polynesians and Europeans in 
New Zealand, with race-specific specialisation of H. pylori 
separate strains. However, this cannot be the reason for H. 
pylori related ethnic differences between Estonians and 
Russians, as far as both nationalities belong to the same 
race. We suppose that different predominant strains may 
be circulating in a particular area.
The Estonian and Russian PPU patients studied by us 
showed similarity in the distribution of age, sex and smok­
ing habits as well as ulcer localisation. Evidently, these 
factors are not closely associated with ethnic tropism of 
H. pylori. Regrettably, we could not follow the socio-eco­
nomic conditions in case of our patients and hence it is 
impossible to conclude if their habits (difference in food or 
health status etc.) have influenced the distribution of H. 
pylori subtypes. In previous epidemiological studies these 
conditions were strongly associated with transmission of
H. pylori infection. In Germany, H. pylori infection was 
established in 6.1% of native German children versus 
44.8% of Turkish children [17]. However, the different in­
cidence of H pylori infection in populations from the
same country but having a different economic background 
does not explain spread of genetically distinct H. pylori 
strains among these populations. Whether the other deter­
minants, e.g. region/country of birth and childhood, or 
microbial adherence and host receptors, determine a par­
ticular distribution of different genotypes of H. pylori 
should be established in further studies with a larger num­
ber of subjects.
The virulence markers differentiating H. pylori strains in 
patients with complicated and uncomplicated peptic ulcer 
have not been assessed up to now. In our study the cagA 
gene of the H. pylori genome was found in 82% of PPU 
patients. The cagA status was similar in samples from 
Estonian and Russian patients with the same underlying 
disease, while the vac A si subtype prevailed in both na­
tionalities (98%). High prevalence of the cagA+ genotype 
and vac A si subtype has been associated with increased 
virulence of H. pylori strains [2,3]. However, recently we 
found predominance of the vacA si gene in another sam­
ple of South Estonian patients suffering either from 
chronic active gastritis or peptic ulcer disease [18]. It is 
likely that the presence of cagA and vac A si genes of
H. pylori strains is not exclusively specific for complicated 
peptic ulcer disease but may merely reflect the circulation 
of predominant strains in a particular geographic region 
of Estonia.
In conclusion, we found diversity in H. pylori genotypes 
among Estonian and Russian patients with PPU from 
South Estonia. This finding points to the need of further 
investigations for future development of novel therapeutic 
targets and vaccines specific for different ethnic groups.
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CORRESPONDENCE
An Attempt at Helicobacter pylori Eradication 
with Intravenous Clarithromycin in 
Perforated Peptic Ulcer Patients
To THE EDITOR: To date, Helicobacter pylori eradication is 
mandatory in all patients with peptic ulcer disease. Mainly 
1-2 week triple or quadruple peroral regimens are advocated. 
However, as opposed to uncomplicated ulcer and peptic ulcer 
with haemorrhage, almost no data are available about the 
application of the above regimens and successful eradication 
of H. pylori in perforated peptic ulcer (PPU) patients.
A non-standard intravenous regimen has already shown 
promising results in peptic ulcer patients. Thus Friess and co­
authors (1) followed eradication of H. pylori in proximal 
vagotomy patients after a perioperative prophylactic single 
dose of mezlocilline and metronidazole. In a 3-month follow- 
up, eradication of H. pylori was achieved in 85% of patients. 
In other reports, H. pylori eradication rates have ranged from 
44% (2) to 87% (3) in peptic ulcer bleeding patients and were 
93% in gastroduodenal ulcer disease patients (4) using 
intravenous regimens.
Although the metronidazole resistance of H. pylori is high 
in Estonia (46%), no clarithromycin resistance has been 
registered (5). Clarithromycin monotherapy has been demon­
strated to display one of the highest monotherapy eradication 
rates in vivo. However, in combination with other antibiotics 
and acid suppressive compounds it has been shown to 
increase eradication rates notably (6). For example, when
clarithromycin was used in combination with ranitidine 
bismuth citrate, eradication of H. pylori was achieved in 
82% of cases in uncomplicated ulcer patients (7). As 
clarithromycin had not been introduced in Estonia before 
this study, one might expect no resistance of H. pylori to this 
compound. Hence we supposed that it might be advantageous 
to use clarithromycin treatment for eradication of H. pylori 
infection in our PPU patients immediately after operation. As 
a pilot study, intravenous infusion of Klacid (0.5 g b.i.d.) was 
used for 5 days in 6 consecutive PPU patients starting from 
the 1st postoperative day. No antacids were applied at the 
time of treatment and in case of need only cefamandol 
(Mandol) was used (3 g per day) for peritonitis cure in 4 
patients. In all patients, 2 specimens from the gastric corpus 
and 2 from the antrum for histological examination of H. 
pylori were collected through the perforation with flexible 
forceps during operation and 6 weeks after eradication on 
panendoscopy. The specimens were fixed overnight in neutral 
buffered formalin, embedded in paraffin, and tissue sections 
were stained by the modified Giemsa method. H. pylori was 
determined semiquantitatively as in our earlier studies (8). 
The study was approved by the Tartu University Ethics 
Committee and informed consent was obtained from each 
subject.
Patient characteristics and the results of H. pylori eradica­
tion are presented in Table I. Only slight score differences 
were seen between H. pylori colonization of the gastric 
antrum and corpus mucosa before and after treatment. 
Eradication of H. pylori was achieved in not one patient 6 
weeks after treatment. The reason for this could not be 
clarithromycin resistance, as no resistant strains (MIC ranges
Table I. The results of Helicobacter pylori eradication with 5-day (0.5 g b.i.d.) intravenous clarithromycin regimen in perforated peptic ulcer 
patients
Helicobacter pylori density on microscopy*
Patient Ulcer location Operation Before treatment 6 weeks after treatment
1. 48 years male Corpus Ulcer suturation Antrum no data Antrum+
Corpus no data Corpus++
2. 46 years male Bulbus Ulcer excision Antmm++ Antrum f+
Corpus+ Corpus
3. 42 years male Pylorus Ulcer suturation Antrum+++ Antrum+++
Corpus++ Corpus++
4. 61 years male Pylorus Truncal vagotomy +  pyloroplasty Antrum++ Antmm++
Corpus++ Corpus"1"
5 57 vears male Pylorus Truncal vagotomy +  pyloroplasty Antrum++ Antrum++
Corpus+++ Corpus++
6. 70 years female Bulbus Ulcer excision Antrum + Antnjm+++
3 Corpus Corpus
* H. pylori density.
-  No H. pylori.
+ Grade 1: <20 microbes per field.
++ Grade 2: 20-60 microbes per field. 
+++ Grade 3: >60 microbes per field.
© 2001 Taylor & Francis
1120 Correspondence
<0.016-0.75 mg/L) had been detected before the year 1999 
(5). Also, it has been proved that clarithromycin is concen­
trated in gastric juice in comparison with plasma and its 
concentration in gastric juice after intravenous administration 
does not depend on the circumstance whether omeprazole was 
со-administered or not (9). Meanwhile, it has also been 
proved that clarithromycin activity is reduced in an acid 
milieu (10). Being aware that even truncal vagotomy could 
not be sufficiently effective for adequate acid suppression, we 
still used the same regimen without any proton-pump 
inhibitors, irrespective of whether or not the acid suppressive 
component (vagotomy) in a pilot study was involved in the 
operation. The evaluated intravenous regimen for H. pylori 
eradication was unsuccessful in the case of either option and 
we abandoned its application. However, although this 
particular monotherapy was unsuccessful, in our opinion the 
idea of immediate postoperative H. pylori eradication in 
complicated peptic ulcer patients seems to deserve further 
investigation, especially when combining several antibiotics 
and acid suppressive compounds.
T. Sillakivi (correspondence)
M. Peetsalu 
M. Mikelsaar 
A. Peetsalu
Dept, of Surgery, University of Tartu 
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Gastric biopsy specimens from 156 adult patients from southern Estonia suffering from chronic gastritis, 
peptic ulcer disease, and perforated peptic ulcer were analyzed by PCR. The cagA gene was evenly distributed 
throughout 87% of the specimens from the patients with the different gastric diseases. The presence of the cagA 
gene correlated with that of vacA signal sequence type sla (99%). However, no clear differences were found in 
the distribution of cagA and vacA genotypes among patients in Estonia with severe perforated peptic ulcer, 
uncomplicated peptic ulcer, or chronic gastritis.
Helicobacter pylori colonizes approximately half of the 
world’s human population (6). It is considered the etiological 
agent of chronic gastritis (CG) and peptic ulcer and their 
complications (3, 14, 15, 21). In Estonia, antibodies against H. 
pylori have been detected in 80% of the inhabitants (12, 13, 
30). Moreover, peptic ulcer disease (PUD) (both gastric and 
duodenal) is widespread in Estonia (13), and the incidence of 
perforated peptic ulcer (PPU) in particular is very high (21 of
100,000 cases) (19).
According to the literature, virulent cytotoxin VacA- and 
CagA-producing strains are more common among patients 
with peptic ulcer and gastric cancer (2,4). Yet in many studies, 
patients with a variety of clinical symptoms of gastritis, gastric 
ulcer, duodenal ulcer, and reflux esophagitis have been exam­
ined for similar virulence markers of H. pylori (26, 27). It has 
not been resolved whether differences in the pathogenesis of 
this spectrum of diseases may be related to particular virulence 
markers differentially expressed by strains of H. pylori.
The aim of the present study was to compare the distribu­
tions of well-known virulence markers (cagA and vacA) in H. 
pylori strains isolated from southern Estonian patients suffer­
ing from CG, PUD, and PPU.
This study was carried out at Tartu University Clinic (Tartu, 
Estonia) between 1995 and 2000. Samples were collected from 
156 adult patients from southern Estonia with CG, PUD, and 
PPU. Initially, 105 patients were investigated from 1 May 1995 
to 30 April 2000, following referral to the Tartu University 
outpatient clinic for upper gastrointestinal endoscopy. In ad­
dition, samples were collected from 51 patients who were op­
erated on for PPUs during the period from 1 January 1997 to 
31 December 1999.
For the detection of CG and PUD, H. pylori strains were 
isolated from biopsy samples obtained by endoscopy. Upper 
endoscopy was performed with an Olympus GIF 21 gastro- 
scope. Endoscopic diagnoses of PUD were made for 69 pa-
* Corresponding author. Mailing address: Department of Microbi­
ology, University of Tartu, Ravila 19, Tartu 50411, Estonia. Phone. 372 
7 374 171. Fax; 372 7 374 172. E-mail: marikam@ut.ee.
tients (duodenal ulcer in 61 patients and gastric ulcer in 8 
patients), and diagnoses of no PUD were made for 36 patients, 
in whom CG was diagnosed histologically according to the 
Sydney classification method (16).
For H. pylori isolation, the biopsy samples from 93 patients 
with CG and PUD were placed into Stuart transport medium 
and taken to the laboratory within 2 h. H. pylori was isolated on 
a Columbia agar base supplemented with 7% horse blood and 
1% IsoVitaleX. The plates were incubated for 3 to 4 days at 
37°C under microaerophilic conditions (CampyGen; Oxoid).
H. pylori was identified by Gram staining and by oxidase, cata- 
lase, and urease reactions. The H. pylori suspension in brucella 
broth was stored at —70°C until DNA extraction. For DNA 
isolation from H. pylori cells, the suspension was incubated at 
100°C for 30 min and the lysates were stored at -20°C prior to 
PCR analysis. For patient samples (n = 12) for which attempts 
to cultivate H. pylori were unsuccessful, biopsy samples stored 
at -20°C in lysis buffer (200 mM Tris-HCl [pH 8.0), 25 mM 
EDTA, 300 mM NaCl, 1.2% sodium dodecyl sulfate) were 
used for PCR analysis.
From the 51 PPU patients, gastric specimens of the antral 
mucosa were obtained for molecular analysis intraoperatively 
through the perforation or postoperatively with panendoscopy. 
These biopsy samples were placed directly into the aforemen­
tioned lysis buffer. For DNA extraction from the frozen gastric 
biopsy specimens, we used a previously described procedure 
(20).
The presence in each strain of cagA and vacA was deter­
mined by PCR using primers, reaction mixtures, and thermal 
cycling (20). PCR products were identified by electrophoresis 
on 2% agarose gels.
Statistical analysis was performed by the two-tailed x2 test or 
by Fisher’s exact test. Significance was set at a P value of <0.05.
Among the 156 patients infected with H. pylori strains, no 
sib strains were found. Multiple H. pylori strains were detected 
in 5 (3.2%) of the 156 patients studied; these included 3 pa­
tients with duodenal ulcer disease, 1 patient with CG, and 1 
patient with PPU. The results from those patients were not 
included in the following analysis.
Among the 151 remaining investigated samples, the cagA
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TABLE 1. Relationships between vacA signal alleles and cagA 
status of 151 H. pylori clinical isolates (P < 0.001)
vacA subtype
No. (%) of isolates
cagA ' cagA negative
sla 131 (99) 4(21)
s2 1(1) 15 (79)
Total 132(100) 19(100)
gene was detected in 132 (87%) of them. Concerning vacA 
subtypes, the sla/ml allelic combination was the most preva­
lent (65%), whereas combinations of sla/m2 and s2/m2 were 
found in 24 and 11 % of the cases, respectively.
The presence of the cagA gene correlated with that of vacA 
signal sequence type sla, whereas type s2 was predominantly 
found in cagA -negative strains (P < 0.001) (Table 1). The 
relationships between cagA status, vacA subtypes, and disease 
in patients are shown in Table 2. In CG and PUD patients, all 
cagA -negative isolates were associated with the s2/m2 geno­
type. In contrast, for the PPU group, four cagA-negative iso­
lates exhibited the vacA genotype sla and conversely, one 
cagA-positive isolate exhibited the vacA genotype s2. However, 
statistically the PPU group results do not differ from those of 
the CG and PUD groups (P >  0.05), with the results of all 
three demonstrating the same correlation between cagA posi- 
tivity and vacA sla type.
This paper provides a comparison of the distributions of H. 
pylori cagA status and vacA genotypes in selected Estonian 
patients with confirmed diagnoses of CG, PUD, and PPU. 
Different consensus criteria for the role of H. pylori have been 
set for populations with high and low prevalences of H. pylori 
infections (11). We attempted to determine whether the same 
set of criteria was valid for a population with a high prevalence 
of H. pylori. In Estonia, according to serological studies, H. 
pylori prevalences are 87% in adults and 56% in children (28, 
30).
In a study by Vorobjova et al. (29), high prevalences of the 
CagA protein in sample populations of Estonian adults (63%) 
and children (46%) have been demonstrated. In the present 
study, we found that the prevalence of the cagA gene among 
the large sample of patients with various clinical diagnoses was 
very high (87%). This corresponds to the findings of a previous 
study, which described a high (82%) prevalence of the cagA 
gene in cases of clinically complicated PUD (20). In addition, 
the present study hints that the cagA gene of H. pylori and its 
defined protein are important predictors of several different
gastric diseases, even in populations with a high prevalence of 
infection.
In countries with a low prevalence of cagA positivity (1,2, 
18), a significant correlation between vacA subtypes and cagA 
status has been demonstrated. In our study of Estonian pa­
tients, a significant association between vacA subtypes and 
cagA status was also found. In particular, 87% of the cagA- 
positive strains had the vacA sla/ml/m2 subtype and only 1 
strain out of the 131 cagA -positive strains carried the vacA 
s2/m2 subtype.
According to a large number of studies (1, 2, 4, 7, 24), the 
vacA sla/ml subtype is considered more cytotoxic than the 
sla/m2 and s2/m2 vacA genotypes and is therefore related to 
the development of PUD. The s2 strains are rarely associated 
with PUD and are more common in cases of CG or nonulcer 
dyspepsia (5, 7, 18, 22, 25). In our study, there was no differ­
ence in colonization by H. pylori cytotoxic strains between 
patients with peptic ulcer and those with the more severe PPU. 
Furthermore, few H. pylori strains were of the s2 subtype (6% 
in PUD patients and 10% in PPU patients). It could be spec­
ulated that, in these patients, the patchy distribution of gastric 
mucosa obscures the sla strain, whereas the s2 strains are 
cocolonizers of the mucosa. Such colonization of the gastric 
mucosa with several different H. pylori strains has been de­
scribed previously in numerous reports (8, 10, 17, 23). The 
cag/)-positive strains from the CG patient samples exclusively 
carried the sla subtype of the vacA gene. Within this group, 
however, the proportion of cagA -negative and vacA s2 alleles 
was the highest (20%) of all the disease groups. Therefore, the 
unusual result may depend on the severity of gastritis in these 
patients.
One important finding regarding the PPU group is that a 
small number of patients (8%) were apparently colonized by a 
cagA-negative strain that simultaneously expressed the vacA 
sla subtype. Consequently, the possibility cannot be excluded 
that additional virulence markers of H. pylori contribute to the 
development of PPU in some patients with PUD, indicating a 
role foT microbial as well as host genetic diversity.
The present study has also confirmed the findings of a pre­
vious investigation on geographic differences in the distribu­
tion of H. pylori strains (20). In the extended sample of 151 
patients examined in the present investigation, no sib subtype 
was detected. Our findings are similar to those for a population 
in Asia (Helicobacter pylori Study Group, Abstr. 9th Int. Work­
shop Gastroduodenal Pathol. Helicobacter, GUT 39(Suppl. 
2):A73-A74, 1996) and one in Poland, for which Gošciniak et 
al. (9) found only 1 of 72 strains with the sib type. Findings
TABLE 2. Relationship between H. pylori cagA status, vacA subtypes, and disease of patient group (P > 0.05)
No. (%) of isolates in patients with:
vacA subtype CG (n = 35) PUD (л = 66) PPU (л = 50)
cagA * (л =  29) cagA negative (л = 6) cagA* (n =  62) cagA negative (n = 4) cagA* (л = 41) cagA negative (л = 9)
s la /m l 23(79) 0 43 (69) 0 29(71) 3(33)
sla/m2 6(21) 0 19(31) 0 11(27) 1(11)
s2/m2 0 6(100) 0 4(100) 1(2) 5(56)
Total 29 (100) 6(100) 62 (100) 4(100) 41(100) 9(100)
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very different from ours have been established in several stud­
ies conducted in The Netherlands, Portugal, Brazil, Mexico, 
and the United States (1, 5, 17, 24). Our findings relate to the 
widely disparate evolutions of circulating H. pylori strains in a 
particular geographic area and the subsequent necessity for 
area-specific diagnostics for H. pylori virulence markers.
In conclusion, we found a high prevalence of the cagA gene 
of H. pylori within the population of strains studied. However, 
no clear differences existed in the distributions of cagA and 
vacA genotypes in Estonia between patients with severe PPU, 
uncomplicated PUD, or CG.
This study was supported by granLs 4898 and 3310 from the Estonian 
Science Foundation and by Base Funding 0418.
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Perforeerunud peptilise haavandi (PPH) 
epidemioloogia on viimastel aastakümnetel oluliselt 
muutunud. A renenud riik ides on PPH 
esinemissagedus vähenenud noortel patsientidel 
ja meestel ning suurenenud eakatel patsientidel ja 
naistel (1), seejuures on kasvanud PPH-ga 
patsientide keskmine vanus, naiste osakaal, 
mittesteroidsete põletikuvastaste ainete (MSPVA) 
tarvitajate ning kaasuvate haigustega patsientide 
arv (2, 3). PPH kirurgilises ravis on toimunud 
muutused mittedefinitiivsefe operatsioonide kasuks 
(4). Sellisele ravitaktikamuutusele on kõige 
olulisemat mõju ava ldanud postoperatiivne 
Helicobacter pylori eradikatsioonile suunatud ravi.
Tartu piirkonnas on aastatel 1991 -9 7  (võrreldes 
perioodiga 1978-90) aset leidnud järsk PPH 
esinemissageduse kasv, sarnane tendents on olnud 
omane õigu.poolest kogu Eestile. Samas ei ole 
oluliselt muutunud PPH-ga patsientide vanus ega 
sooline koosseis (5). PPH esinemissagedus aastatel 
1991-97 (1 6 -2 6  juhtu 100 000 inimese kohta 
aastas) ületab 2 -1 0  korda viimaste aasta­
kümnendite vastavaid näitajaid (2 ,3 -1 0  juhtu 
100 000 inimese kohta aastas) arenenud riikides 
(3,6, 7).
Selle uuringu eesmärgiks oli välja selgitada PPH 
suure esinemissageduse võimalikke põhjuseid Eesti 
patsientidel. Püüdsime hinnata PPH riskifaktorite 
esinemist, tüsistusele eelnenud diagnostikat ning 
praegusaegsete le  arusaam adele vastavat 
haavand irav i nendel pa ts ien tide l enne 
perforatsiooni teket.
Uurim ism aterja l ja  -m e eto d id
Prospektiivne uuring hõlmas kõiki ajavahemikul
1. jaanuarist 1997. a kuni 31. detsembrini 1999. a
Tartu Maarjamõisa Haiglasse hospitaliseeritud 129 
PPH-ga patsienti. Iga patsiendi kohta täideti pre- ja 
postoperatiivselt spetsiaalsed protokollid, mis 
hõlmasid ka põhjalikku elu-ja haiguse anamneesi, 
sealhulgas võimalikke PPH riskifaktoreid (stress, 
pats iendi sotsiaalne staatus, suitsetam ine, 
mittesteroidsete põletikuvastaste ainete kasutamine 
ning eelneva haavandtõveravi kasutamine või 
mittekasutamine), millele on viidatud eelnevates 
uuringutes (1,8, 9). Tüsistusele eelnenud perioodil 
patsiendile tehtud haavndtõveravi klassifitseeriti 
järgmiselt: ravi vajaduse korral (vaevuste tekkel 
ravim ite tarv itam ine mõne päeva jooksul), 
vahelduvravi (1 -2  kuud kestev ravi haiguse 
ägenemise a ja l) ning säilitusravi (ravim ite 
igapäevane tarvitamine vähemalt viimase 3 kuu 
jooksul) (10). H. py lori identifitseerimiseks koguti 
patsientide juhusliku valiku alusel 2 antrumi ja 2 
maokorpuse limaskesta proov itükk i kas 
operatsiooni ajal biopsiatangidega läbi perforat- 
siooniava või postoperatiivselt panendoskoopial.
H. py lo riesinemist hinnati 96 juhul histoloogiliselt, 
kasutades Giemsa värvingut, ning 53 juhul 
täiendavalt antrumi limaskesta biopsiamaterjali 
uurides PCR (po lüm eraasahelreaktsioon) 
metoodika abil (11). Väljalõigatud haavandit või 
haavandi servast võetud proovitükk i uuriti 
histo loogilise lt hem atoksüliineosiinvärvingut 
kasutades 77 patsiendil.
Tulemused
Prospektiivse uuringu perioodil aastatel 1997-99 
hospitaliseeriti Tartu Maarjamõisa haiglasse 129 
PPH-ga patsienti keskmise vanusega 48,6 aastat 
(96 meest keskmise vanusega 42,8 a ja 33 naist 
keskmise vanusega 65 ,6 a). 111 juhul esines
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duodenaalhaavandi ja 16 juhul maohaavandi 
perforatsioon. Arvestades ainult Tartu piirkonda 
sisse kirjutatud patsiente, olid PPH esinemis­
sageduse näitajad aastatel 1997-99 vastavalt 26, 
17 ja 22 juhtu 100 000 inimese kohta aastas.
Ainult 30%-l patsientidest oli haavandtõbi 
diagnoositud enne perforatsiooni teket (12% 
endoskoopiliselt, 4% röntgenoloogiliselt, 12% 
mõlema m eetodi ab il ning 2% varasemal 
perforatsiooni tõttu tehtud operatsioonil) (vt jn 1). 
Aeg haavandi diagnoosimisest kuni perforatsiooni 
tekkeni varieerus 2 kuust kuni 45 aastani (mediaan 
8 aastat). Lisaks oli veel 53%-l patsientidest 
eelnevalt esinenud haavandtõvele iseloomulikke 
ülakõhukaebusi. Seejuures 78% kõigist patsientidest 
ja 44% nendest, kellel haavandtõbi oli eelnevalt 
diagnoositud, ei olnud viimase aasta jooksul 
haavandtõveravimeid tarvitanud (vt jn 2), ainult 1 
patsient (3%) oli tarvitanud omeprasooli. Mitte ükski 
129 patsiendist po lnud saanud H. p y lo r i 
eradikatsioonile suunatud ravi. 11% patsientidest 
tarv itas p ideva lt MSPVA-d (vt jn 3). 77% 
patsientidest olid suitsetajad ning 63% tunnistas 
stressi esinemist (patsiendi enda subjektiivne 
hinnang) (vt jn 4). 24%  patsientidest o lid 
pensionärid, 41% töötasid ning 20% olid töötud 
või elatusid juhutöödest.
H isto loogilise lt (Giemsa värving) uuritud 
maolimaskestatükkides oli 97%-l juhtudest (93/96) 
sedastatav H. p y lo riesinemine, seda tõestasid ka 
PCR (polümeraasahelreaktsioon) metoodikal
tehtud antrumi limaskestauuringud -  H. py lo ri oli 
sedastatav 96%-l juhtudest (51 /53). Kõigil 77  
patsiendil, kellel uuriti haavandit histoloogiliselt, 
oli tegemist kroonilise haavandi perforatsiooniga.
Arutelu
Sarnaselt meie retrospektiivse uuringuga (5) olid 
ka selle prospektiivse uuringu patsiendid oluliselt 
nooremad (keskmine vanus 48 aastat vs53 -63  a 
lääneriikides) ning naiste osakaal väiksem (26% 
vs40-69%  lääneriikides) kui enamikus arenenud 
riikides tehtud uuringutes (2, 3, 6, 12). Seevastu on 
patsientide jaotus meie uuringus ja 1997. a Ida- 
Euroopa riikides tehtud uuringus (Copernicuse 
programm - ägeda kõhuvalu uuring Ida-Euroopas) 
sarnased (13).
Selle uuringu tulemused viitavad mitmetele 
faktoritele, mille koosmõju on ilmselt viinud järsule 
PPH esinemissageduse kasvule, ning sellele, miks 
viimase aastakümnendi nä ita jad  arenenud 
riikidega võrreldes on sedavõrd suured.
1. Ühiskondliku stressi osa. Sarnaselt PPH 
esinemissageduse kõvera järsu tõusuga aastast 
1991 on käitunud ka suitsiidikõver Eestis (14). 
Analoogiline PPH esinemissageduse oluline kasv 
esines ka Hong-Kongis pärast iseseisvumist, mil 
tõsiste poliitilis-majanduslike muutuste foonil 
märgati ka stressi suurenemist ühiskonnas (8).
2. Sotsiaalsed fak to rid . Uuritud PPH-ga 
patsientide seas oli rohkelt nn madalama sotsiaalse 
klassi esindajaid (ainult 41 %-l oli stabiilne töökoht).
Joonis 1. PPH-ga patsientide osakaal, kellel on varem diagnoositud haavandtõbi või esinenud ülakõhukaebused
Kõik patsiendid
Omeprasool
1%
H2 blokaator 
21%
Need, kellel haavandtõbi oli varem d iag­
noositud
H2 blokaator 
säilifusravi 
O m eprasool 5%
3%
H2 blokaator 
vajadusel 
24%
Joonis 2. Haavandtõve varasem ravi PPH-ga patsientidel
MSPVA tarvitamine Suitsetamine
pidevalt
11%
aeg-ajalt 
25%
33%
Joonis 3. Mittesteroidsete põletikuvastaste ainete (MSPVA) tarvitamine ja suitsetamine PPH-ga patsientide hulgas
Stress anamneesis
tööline
41%
Sotsiaalne staatus
õpilane/ 
ülalpeetav 
invaliid 5%
10%
pens ionä r
töötu/juhutöö
20%
Joonis 4. Stress ja sotsiaalne staatus PPH-ga patsientidel
3. Suitsetamine. PPH-ga patsientidest oli 
suitsetajaid 77%; suitsetamise rollile PPH tekkes on 
viidatud ka teistes uuringutes (1).
4. Eelneva diagnostika puudused. Väga suurel 
osal PPH-ga patsientidest (70%) oli eelnevalt 
jäänud haavandtõbi diagnoosimata, kuigi 53% l 
patsientidest esinesid haavandtõvele iseloomulikud 
ülakõhukaebused. Põhjuseks on ilmselt ka 
patsientide vähene haigusteadlikkus ning arstiabi 
raskem kättesaadavus mõnes sotsiaalses rühmas.
5. Nüüdisaegse medikamentoosse haavandi- 
ravi puudumine enne perforatsiooni teket. 44% 
haavand id iagnoosiga patsientidest polnud 
perforatsioonile eelnenud aasta jooksul saanud 
haavand irav i. Varasemates uuringutes on 
näidatud, et p ikaa ja line  säilitusravi H2-blo- 
kaatoriga vähendab oluliselt perforatsiooniriski 
mitteravitud haavandihaigetega võrreldes (9). 
Ükski haige po lnud saanud H. p y lo r i 
eradikatsioonile suunatud ravi. Kui võrrelda meie 
uuringu tulemusi 1995. a Eestis tehtud uuringuga 
(10), siis näeme, et olulist muutust pole toimunud. 
Ka 5 aastat tagasi tehtud küsitlus näitas, et kuigi 
sä ilitusravi ja H. p y lo r i ravi p idasid 
haavandtõvehaigetel õigeks 34-84%  arstidest, 
kasutati sellist ravi tegelikkuses vaid 0-20% -l 
patsientidest. Tuleb siiski märkida, et erinevalt 
1995. aastal arstide küsitluse teel saadud 
andmetest oleme meie oma uuringus hinnanud 
patsientidelt saadud andmeid reaalselt kasutatud 
ravi kohta.
Meie uuringu tulemused näitavad, et H. pylori 
esinemine PPH-ga haigetel on väga sage (97% vs 
50-83%  arenenud riikides) (15, 16). Kas PPH 
esinemissageduse muutused ja sedavõrd suur 
H. py lo rlqa  infitseeritus on seotud, pole siiski 
selge. Kuigi H. py lori eradikatsioon on saanud 
põhiliseks argumendiks haavandtõve mittedefi- 
nitiivse operatiivse ravitaktika pealetungil, pole 
H. pylori roll perforatsioonide puhul, erinevalt näi­
teks haavandiverejooksudest, lõplikult selge (15, 16).
Kokkuvõte
Võib öelda, et PPH esinemissagedus Eestis on 
viimasel kümnendil jätkuvalt väga suur. Meie 
patsientidel esinevate riskifaktorite seast võiks välja 
tuua H. py lo ri suure esinemissageduse, stressi, 
sotsiaalsed probleemid, suitsetamise. Haavand- 
tõbe diagnoositakse enamikul haigetest alles 
perforatsiooni tekkel. Ka eelnevalt diagnoositud 
haavandtõvega patsiendid polnud sageli saanud 
adekvaatset medikamentoosset ravi, kusjuures 
H. p y lo r i eradikatsiooni rakendamine ravis 
puudub üldse.
Olukorra parandamiseks tuleb vähendada 
peptilise haavand i e luohtliku tüsistuse -  
perforatsiooni tekkeohtu. Vastavad meetmed 
peavad olema suunatud ühelt poolt arstkonnale, 
kes peaks paremini ära kasutama haavandtõve 
tänapäeva ravivõimalusi, ja teiselt poolt tuleb 
tõhustada selgitustööd inimeste seas, et 
suurendada haigusteadlikkust ning julgustada 
pöörduma arsti poole.
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Summary
Risk factors o f perforated peptic ulcer
The aim of ihe study was to clarify possible 
causes of the high incidence of perforated peptic 
ulcer in Estonian patients by assessment of risk 
factors, including pre-complication diagnostics and 
use of ulcer treatment, on the basis of contemporary 
knowledge, in these patients before development 
of perforation.
The prospective study comprised all 129 
perforated peptic ulcer patients who were admitted 
to Tartu Maarjamõisa Hospital in 1997-1999.
In 70% of our patients ulcer disease had not 
been diagnosed before development o f the 
complication, and even 44% of patients with 
previously proved ulcer diagnosis had not taken 
drugs against ulcer disease (H2- blockers, proton
pump inhibitors). No patient had passed treatment 
for Helicobacter pylori. O f the patients 77% were 
smokers, 63% mentioned stress in everyday life and 
in 97% H. yD//o/y'infection was detected in the gastric 
mucosa. The high incidence of perforated peptic 
ulcer can be related to high H. py lo ri infection 
among our patients as well as to frequent smoking, 
stress and social problems. No one patient had 
undergone H. p y lo r i eradication prior to the 
complication. To reduce the incidence of this life- 
threatening complication, proper measures should 
be directed to the raising of the awareness of both 
the medical staff and patients.
toomas.sillakivi@kliinikum.ee
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HeHtobatter pyfori eradikalsioon  
perforeerunud peptilise haavandiga h a ig e te l
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T oom as Sillakivi1, M argot P eetsa lu 1, M arika M ik elsaar3, Ants P eetsa lu 1 -
'TÜ kirurgiakliinik, 2TÜ mikrobioloogia instituut
perforeerunud peptiline haavond, H. pylori eradikatsioon
Tartu piirkonnas (aga ka kogu Eestis) on alates 
1991. a järsult suurenenud perforeerunud peptilise 
haavandi (PPH) esinemissagedus, kusjuures 
H. p y lo r i esinemine meie PPHga patsientide 
maolimaskestas ulatub 96-97%-ni (1).
PPH kirurgilise ravi taktika on kogu maailmas 
muutunud mittedefinitiivsete operatsioonide (s.o 
perforeerunud haavandi üleõmblus ja ekstsisioon) 
kasuks, mida on suures osas põhjendatud just 
H. pylori postoperatiivse eradikatsioonivõimaluse 
lisandumisega (2). Haavandiverejooksude korral 
on H. p y lo r i eradikatsioon andnud positiivseid 
tulemusi: on vähenenud verejooksu ja haavandi 
retsidiivi võimalus (3, 4). Perforatsioonide puhul 
pole aga H. pylori eradikatsiooni efektiivsus senini 
üheselt selge.
Pikaajalised uuringud (patsiente on jälgitud kuni 
14 a pärast operatsiooni) on näidanud, et peaaegu 
kõigil duodenaalhaavandiga haigetel on mao 
limaskest H. p y lo ri infektsioonist haaratud ning 
vagotoom ia kui efektiivne ravim eetod, mis 
vähendab külJ happe-peptilist faktorit, ei elimineeri 
H. p y lo r i  ko lon isa ts ioon i maost ning 
retsidiivhaavandite arv kasvab aja jooksul pidevalt 
pärast operatiivset ravi (5). Seepärast oleks 
otstarbekas operatiivse ravi ajal või selle järel 
PPHga haigetel teha ka H. p y lo rf\ elimineeriv 
ravikuur, et vähendada retsidiivhaavandite teket. 
Kirjanduse andmetel on sellist taktikat proovitud 
ainult üksikutel juhtudel, kuigi H. py lo ri eradikat­
siooni tulemused on olnud paljulubavad. Nii jälgis 
Friess kaasautoritega (6) tüsistumata duodenaal­
haavandiga haigetel H. p y lo r i eradikatsiooni 
efektiivsust ühekordse opera ts ioon iaegse 
antibiootikumprofülaktika järel (meslotsilliin ja
metronidasool) ning saavutas pärast 3-kuulist 
jä lgim isaega H. p y lo r i eradikats iooni 85%-l 
haigetest. Ng kaasautoritega (7) kasutas PPHga 
haigetel vahetus postoperatiivses perioodis 
pe roraa lse t ne lik rav i (vismut subtsitraat, 
tetratsükliin, metronidasool ning omeprasool) ning 
sai hea eradikatsioonitulemuse (83%).
Käesoleva uuringu eesmärgiks oli leida PPHga 
patsientidele Eestis H. p y lo r i eradikatsiooniks 
efektiivne postoperatiivne raviskeem.
Uurim ism aterjal ja -m e e to d id
Tartu Maarjamõisa Haiglas korraldati aastatel 
19 97 -199 9  prospektiivne uuring, kus PPHga 
patsientidelt koguti operatsiooni ajal biopsia- 
tangidega läbi perforatsiooniava 2 antrumi ja 
2 maokorpuse limaskestabioptaati Helicobacter 
p y lo r i  identifitseerim iseks. H. p y lo r i 
eradikatsiooniks kasutati 6 erinevat raviskeemi 
49  m ittejärjestikusel patsiendil kas vahetult 
postoperatiivselt haiglas (intravenoosne 5-päevane 
ravi) või ambulatoorselt 7 -1 0  päeva möödumisel 
operatsioonist (peroraalne 7-päevane ravi) (vt 
tabel 1). Kaks peroraalset kolmikraviskeemi (I ja 
II), mida me kasutasime mittevagotomeeritud 
patsientidel, on maailmas laialt levinud, need on 
nn klassikalised kombinatsioonid: amoksitsilliini 
1000 mg b.i.d. + metronidasooli 500 mg q.i.d. + 
omeprasooli 20 mg b.i.d. (8 patsienti) ning 
amoksitsilliini 1000 mg b.i.d. + klaritromütsiini 
500 mg b.i.d. + omeprasooli 20 mg b.i.d. (11 
patsienti). V iim ati nimetatud raviskeemi on 
soovitanud ka Eesti Gastroenteroloogide Selts (8). 
Ülejäänud meie kasutatud raviskeemid (III-VI) olid 
modifitseeritud: neist amoksitsilliini 1000 mg b.i.d.
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Ravi skeem Haigete
arv
Keskmine 
vanus (a)
M e h i/
naisi
Duodenaa!- /  
maohaavand
Eradikatsioon 
patsientide arv (% )
1 AKO* p.o. 7 päeva 11 40,0 l l / O 9 /2 2 (18,2)
II A M O * p.o. 7 päeva 8 31,9 8 /0 8 /0 3 (3Z5)
III AM ** p.o. 7 päeva 16 46,2 15/1 16 /0 4  (25,0)
IV AK ** p.o. 7 päeva 6 3 7 7 5/1 6 /0 1(16,7)
V KLACID*** i.v. 5 päeva 6 54,0 5/1 5 /1 0 (0 )
VI KLACID*** p.o. 7 päeva 2 54,0 1/1 1/1 0 (0 )
VII KONfmOLLGRUPP*** 10 46,1 8 /2 6 /4 0 (0 )
A  - amoksitsilliin (AinoxidHin-raoopharm® I g b.i.d.
К  - klaritromütsiin (Klacid®, Abbott) 0,5 g b.i.d.
M - metronidasool (Metronidazole BP®, Pharmachem) 0,5 g q.i.d.
О  - omeprasool (Losec®, Astra) 20 mg b.i.d.
KONTROLLGRUPP - patsiendid, kelle! H . pylori eradikatsiooni ei tehtud
*  -  m ittevagotomeeritud patsiendid
* *  - ilma prootonpumba inhibiitorita ravitud patsiendid, kellel operatsioonil tehti ka trunkaalne vagotoomia 
* * *  - nii vago to  meeritud kui ka vagotomeerimata patsiendid
+ metronidasooli 500 mg q.i.d. (16 patsienti) ning 
amoksitsiiliini 1000 mg b.i.d. + klaritromütsiini 
500 mg b.i.d. (6 patsienti) olid modifikatsioonid 
kahest eelmisest, mida kasutasime vagotomeeritud 
patsientidel, et kontrollida, kas vagotoomia võiks 
sellisel puhul asendada omeprasooli. Klaritro­
mütsiini monoteraapiat (500 mg b.i.d) rakendati 
perioodil, mil see ravim oli Eestis kasutusel alles 
esimesi nädalaid, eeldades, et H. pylori ei ole selle 
preparaadi suhtes resistentne. V grupis (6 patsienti) 
kestis intravenoosne ravi 5 päeva ja VI grupis 
peroraalne monoteraapia 7 päeva (2 patsienti) 
(vt tabel 1). Järelkontrollil 2 -3  kuu möödumisel tehti 
panendoskoopia ning võeti limaskesta proovitükid 
(2 antrumist ja 2 korpusest). H. py lori hindamiseks 
kasutati Giemsa värvingut ning tulemust peeti 
positiivseks, kui H. py lo ri oli sedastatav vähemalt 
ühes preparaadis.
Tulemused
H. py lo ri eradikatsiooniks mõeldud ravi tule­
mused 49 PPHga patsiendil on esitatud tabelis 1. 
Histoloogilise hinnangu alusel saavutati H. py lo ri 
eradikatsioon erinevate raviskeemide kasutamisel 
0 kuni 37,5% juhtudest, kusjuures kontrollrühmas 
(patsiendid, kes polnud saanud H. py lo ri vastast 
ravi) ei toimunud ühelgi patsiendil eradikatsiooni.
2 patsienti (ravi amoksitsiiliini, metronidasooli ja 
omeprasooliga) katkestasid ravi kõrvaltoimete 
(diarröa) tõttu ning need patsiendid on tabelist ja 
analüüsist välja jäetud.
Arutelu
Vastavalt Maastrichti konsensusele 1996. a 
septembrist (9) on tänapäeval H. p y lo r i era­
dikatsiooni soovitatud kõigile peptilise haavandiga 
patsien tide le, ke ile l on tõestatud H. p y lo r i  
olemasolu maolimaskestas. Eradikatsiooni tule­
mused peroraalsete kolmik-või nelikraviskeemide 
puhul ületavad 80 -90%  enamikus publitseeritud 
töödes (10, 11). Samas on väga vähe in for­
matsiooni sellise taktika edukuse kohta PPHga 
patsientide puhul, sest enamasti on need patsiendid 
uuringutest välja jäetud (12).
Meie uuringus toimus H. py lo ri eradikatsioon 
oodatust oluliselt väiksemal osal PPHga patsi­
entidest ja seda ka kahe maailmas laialt levinud 
klassilcälise' kolmikravislceemiga: I rdViskeem 
(amoksitsilliin, klaritromütsiin ning omeprasool), 
mida on soovitanud Eesti Gastroenteroloogide Selts 
(8), andis positiivse eradikatsioonitulemuse ainult 
18,2%-l juhtudest; II raviskeem (metronidasool, 
amoksitsilliin ning omeprasool) andis positiivse era­
dikatsioonitulemuse 37,5%-l juhtudest (vt tabel 1).
Ka modifitseeritud raviskeemid ei andnud rahul­
davat tulemust: eradikafsioon 0-25%-l juhtudest. 
Miks toimus H. py lo ri eradikafsioon meie uuringus 
n iivõ rd  väikesel osal patsientidest, jääb 
ebaselgeks. Võimalike põhjustena tulevad arvesse 
järgmised asjaolud.
1. Meie PPHga patsientidel postoperatiivses 
perioodis tehtud ühenädalased peroraalsed 
ravikuurid, mis on Eestis andnud positiivseid 
tulemusi mittetüsistunud haavandihaigetel, ei sobi 
ilmselt PPH puhul või vajavad need haiged pikemat 
ravikuuri. Ometi on ravi amoksitsilliini, klaritro- 
mütsiini ja omeprasooliga soovitanud Eesti Gastro- 
enteroloogide Selts ning see on andnud 91%-lise 
eradikatsioonitulemuse (13).
2. L iia lt varane (7 .-1 0 . postoperatiivse l 
päeval) ravi alustamine meie PPHga patsientidel. 
Selle põhjuse vastu räägivad teiste uuringute 
tulemused, milles PPHga haigetei juba alates 
3. postoperatiivsest päevast alustatud H. p y lo ri 
ravi oli 83%-l juhtudest edukas (7).
3. Probleemid ravirežiimist kinnipidamisega. 
Seda on peetud üheks olulisemaks H. p y lo r i 
eradikatsiooni ebaõnnestumise põhjuseks (10).
Am bulatoorselt puudub vahetu kontrollim ise 
võimalus ravimite tegeliku kasutamise üle. Kuna aga 
patsiendid ilmusid 2 -3  kuu möödumisel ravikuurist 
korrektselt ambulatoorsele järelkontrollile, kus tehti 
ka patsiendi jaoks ebam eeldiv protseduur -  
endoskoopia, siis viitab see haigepoolsele koos­
töövalmidusele ning H. p y lo r i eradikatsioonisf 
huvitatusele.
Meie uuringu tulemused näitavad, et PPHga 
haigetele sobiva efektiivsema raviskeemi leidmine 
vajab veel edaspidiseid uuringuid. H. p y lo r i 
mikroobitüvede eripära selgitamine PPH puhul võiks 
pakkuda uusi lahendusi ka raviprobleemidele.
K o kku võ tteks  võib öelda, et kõik meie töös 
H. ^ //о л /eradikatsiooniks kasutatud raviskeemid, 
sealhulgas ka Eesti gastroenteroloogide soovitatud 
ravikombinatsioon, ei ole PPHga patsientidel 
eeldatud efekti andnud. PPH suure esinemis­
sageduse ja nende patsientide 96-97,% -lise 
H. p y lo r iga infitseerituse taustal nõuab meie 
oludele sobiva ravitaktika väljatöötamine jätkuvaid 
uuringuid, et vältida postoperatiivselt retsidiiv- 
haavandite ning nendest ting itud eluohtlike 
tüsistuste tekkimist.
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Summary
Eradication of H. pylori in perforated peptic ulcer patients
The aim of the study was to develop an effective 
postoperative regimen fo r H. p y lo r i eradication in 
perforated peptic ulcer patients in Estonia.The treatment 
aimed at H. p y lo r i e radication was app lied  in 49 
perforated peptic ulcer patients in the postoperative 
period using 6 different treatment regimens, including
2 widely recognized triple regimens. The results of H. 
pylo ri eradication were assessed histologically. Gastric 
mucosal specimens were collected at the operation and 
after 2 -3  months of treatment on panendoscopy.
The results of H. p y lo r i eradication in our different 
treatment regimens varied from 0 to 37,5%. Considering 
the extremely high incidence of H. p y lo r i infection and 
the hitherto unsatisfactory results of eradication, it is 
necessary to continue investigations aimed at working 
out an appropriate treatment regimen fo r perforated 
peptic ulcer patients in our conditions.
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